Condensed pyrimidinedione compound, use thereof and pharmaceutical composition
By developing fused pyrimidine dione compounds with 8-ethynyl or vinyl substitution as TRPC4/5 inhibitors, the problems of slow metabolism and systemic side effects of existing drugs in vivo have been solved, achieving rapid metabolism and effective treatment of keratinocyte lesion-related skin diseases.
Patent Information
- Application Number
- CN202211324140.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-10-27
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2042-10-27
AI Technical Summary
Existing TRPC4/5 inhibitors are metabolized slowly in the body, leading to systemic side effects, and there are no effective drugs for targeting and regulating keratinocyte function to treat keratotic skin diseases.
Develop fused pyrimidine dione compounds with 8-ethynyl or vinyl substitution as TRPC4/5 inhibitors, which have a faster hepatic microsomal metabolic rate and higher in vitro activity. These compounds can be used to prepare topical skin medications that are rapidly metabolized by the liver, avoiding systemic side effects, and can be combined with other drugs such as glucocorticoids and Janus kinase inhibitors to treat skin diseases related to keratinocyte abnormalities.
It achieves faster drug metabolism and clearance, reduces systemic side effects, and effectively treats skin diseases related to keratinocyte lesions such as psoriasis and ichthyosis.
Smart Images

Figure CN115636831B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of pharmaceutical chemistry, and in particular to fused pyrimidinedione compounds, uses thereof and pharmaceutical compositions. Background Art
[0002] Transient receptor potential (TRP) ion channels are a class of six transmembrane channel proteins widely distributed in the peripheral and central nervous systems. They are molecular receptors that sense changes in the cell environment, transmit signals, and maintain cell homeostasis. Based on sequence similarity, mammalian TRP ion channels can be divided into six subfamilies: TRPA, TRPC, TRPM, TRPML, TRPP, and TRPV. Classical transient receptor potential (TRPC) channels are non-selective cation channels that allow Ca 2+ 、Na + Through. Mammalian TRPC consists of six members: TRPC1, TRPC3, TRPC4, TRPC5, TRPC6, and TRPC7. The amino acid sequences of TRPC3, TRPC6, and TRPC7 are highly consistent, while the sequences of TRPC1, TRPC4, and TRPC5 are highly consistent. TRP family proteins exist in the form of homozygous or heterozygous tetramers and function as ion channels. TRPC5 easily forms heterozygous tetramers with TRPC1 and TRPC4 (J Med Chem. 2019, 62, 7589.).
[0003] TRPC4 / 5 is expressed in multiple parts of the brain, including the hippocampus, amygdala, frontal cortex, etc., and is associated with the occurrence of central nervous system diseases such as anxiety, depression, epilepsy, and addiction. TRPC4 or TRPC 5 gene knockout, or the use of TPRC4 / 5 inhibitors can relieve anxiety and depression symptoms in mice (PLoS ONE.2018,13,e0191225.). Recent studies have found that TRPC5 is also expressed in glomerular podocytes, and its dysfunction is associated with the formation of chronic kidney disease. TRPC5 gene knockout or the use of TPRC5 inhibitors can reduce proteinuria, protect podocytes, and inhibit the progression of kidney disease (Science.2017,358,1332.). The prior art has studied inhibitors of TRPC4 / 5. For example, patent applications WO2014143799 and WO2019011802 disclose xanthine TRPC4 / 5 inhibitors, and patent applications WO2019055966 and WO2020061162 disclose pyridazinone TRPC4 / 5 inhibitors.
[0004] TRPC4 and TRPC5 are expressed in skin keratinocytes and peripheral sensory neurons, and play an important role in regulating keratinocyte differentiation and pain perception (Pharmaceuticals (Basel). 2016, 9, 77.; Sci Transl Med. 2021, 13, eabd7702.). Keratinocytes are the main component of the epidermis of the skin. They not only constitute a natural barrier for the skin to resist physical, chemical and biological invasions, but also participate in initiating the immune inflammatory response of the skin. Abnormal differentiation and proliferation of keratinocytes lead to the formation of keratotic skin diseases, which manifest as hyperplasia of skin keratin, dry and cracked skin, scaling, itching, etc. Keratinotic skin diseases are divided into two categories: hereditary and acquired, mainly including ichthyosis, palmoplantar keratosis, Olmsted's disease, toad skin disease, menopausal keratosis, etc. Psoriasis is a common chronic inflammatory skin disease characterized by excessive immune cell infiltration in the dermis and epidermis and abnormal keratinocyte differentiation and proliferation. There is increasing evidence that keratinocyte dysfunction is an important factor in the formation, progression, and recurrence of psoriasis, so targeted regulation of keratinocytes has become a new option for the treatment of psoriasis (J Leukoc Biol. 2020, 108, 485.). There have been no public reports on inhibitors of TRPC4 / 5 and drugs containing such inhibitors that can target and regulate keratinocytes. Summary of the invention
[0005] The present invention discloses a fused pyrimidinedione compound substituted with an ethynyl or vinyl group at the 8-position, which can be used as a TRPC4 / 5 inhibitor and is used for preparing a drug for treating skin diseases related to keratinocyte lesions. Compared with existing TRPC4 / 5 inhibitors, the compound disclosed in the present invention has higher in vitro activity and faster liver microsomal metabolism rate. When used to prepare a topical drug for skin application, the compound of the present invention can be metabolized and cleared faster by the liver after being absorbed through the skin. Since TRPC4 and TRPC5 are widely distributed in the physiological tissue structure of humans and also play an important role in maintaining normal physiological functions, a rapidly metabolized TRPC4 / 5 inhibitor can avoid systemic side effects to a greater extent.
[0006] The technical solution adopted by the present invention is:
[0007] A fused pyrimidinedione compound and a pharmaceutically acceptable salt thereof, wherein the structural formula of the compound is as shown in formula (I):
[0008]
[0009] Among them, R 1 is a C1-C6 alkyl group;
[0010] Each R 2 are independently halogen atoms;
[0011] R 3 is selected from substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C3-C 10 substituted or unsubstituted 6-10 membered aryl and substituted or unsubstituted 5-8 membered heteroaryl, wherein R 3 The substituents are 1-3 groups selected from the following groups: C1-C6 alkyl, C3-C8 cycloalkyl, -OR 4 、-N(R 4 )2 and halogen atoms;
[0012] Each R 4 are each independently selected from H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted phenyl, wherein R 4 The substituents are 1-3 groups from the following group: C3-C8 cycloalkyl, halogen atoms, hydroxyl groups and =O; or,
[0013] Two R's 4 connected to form a 4-8 membered substituted or unsubstituted heterocyclic ring, wherein the heteroatoms of the heterocyclic ring are selected from N, O, and S and contain at least 1 N, and the number of heteroatoms is 1 or 2; the substituents of the heterocyclic ring are 1-3 groups independently selected from the following group: C1-C6 alkyl and halogen atoms;
[0014] n is an integer from 1 to 3;
[0015] X is N or CH;
[0016] Y is selected from one of an ethynyl group and a substituted or unsubstituted vinyl group, wherein the substituent of the vinyl group is 1-2 C1-C6 alkyl groups.
[0017] As a further improvement of the technical solution, R 1 It is methyl, ethyl or isopropyl.
[0018] As a further improvement of the technical solution, R 3 C3-C 10 cycloalkyl or C1-C6 alkyl substituted by -OR4 or -N(R4)2.
[0019] As a further improvement of the technical solution, the compound is selected from the structural formulas (II a)-(II c):
[0020]
[0021] in,
[0022] R1 is methyl, ethyl or isopropyl;
[0023] Each R 2are each independently a halogen atom;
[0024] Ring C is substituted or unsubstituted C3-C 10 substituted or unsubstituted phenyl or substituted or unsubstituted 5-8 membered heteroaryl, wherein the substituents of ring C are 1-3 groups selected from the following group: C1-C6 alkyl and halogen atoms;
[0025] R 4 are each independently selected from substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted phenyl, wherein R 4 The substituents are 1-3 groups selected from the group consisting of C3-C8 cycloalkyl and halogen atoms; or,
[0026] Two R's 4 Together with N, they form a 4-8 membered substituted or unsubstituted heterocyclic ring, wherein the substituents of the heterocyclic ring are 1-3 C1-C6 alkyl groups;
[0027] R 5 , R 6 Each is independently H or a C1-C3 alkyl group;
[0028] n is an integer from 1 to 3.
[0029] As a further improvement of the technical solution, the compound is selected from:
[0030]
[0031]
[0032]
[0033] Unless otherwise specified, the terms used in this invention have the following definitions:
[0034] In the present invention, unless otherwise specified, the terms used have the general meanings well known to those skilled in the art.
[0035] In the present invention, the term "C1-C3" refers to having 1, 2 or 3 carbon atoms, the term "C1-C6" refers to having 1, 2, 3, 4, 5 or 6 carbon atoms, and so on. "4-8 membered" refers to having 4, 5, 6, 7 or 8 ring atoms, and so on.
[0036] In the present invention, the "alkyl" is a branched or straight-chain hydrocarbon group having a specific number of carbon atoms, and representative examples include but are not limited to methyl, ethyl, n-propyl, isopropyl, tert-butyl, and the like.
[0037] In the present invention, the "haloalkyl group" refers to a group formed by partially or completely replacing the hydrogen atoms in an "alkyl group" having a specific number of carbon atoms with a "halogen atom".
[0038] In the present invention, the "cycloalkyl" refers to a non-aromatic cyclic aliphatic hydrocarbon group having a specific number of ring carbon atoms, including a monocyclic, fused, bridged, or spirocyclic system. Representative examples include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, decahydronaphthyl, and adamantyl.
[0039] In the present invention, "aryl" is defined as a monocyclic or bicyclic ring system consisting of a specific number of carbon atoms and complying with Hückel's rule, including but not limited to a benzene ring and a naphthalene ring.
[0040] In the present invention, "heteroaryl" is defined as a monocyclic and bicyclic ring system having a specific number of ring atoms and containing 1, 2, 3 or 4 heteroatoms (selected from N, O, S) and obeying Hückel's rule, including but not limited to pyridine, pyrrole, imidazole, and thiophene.
[0041] In the present invention, "heterocycle" is defined as a saturated or partially unsaturated non-aromatic cyclic group consisting of a specific number of ring atoms, and containing 1, 2, 3 or 4 heteroatoms (selected from N, O, S) as ring atoms, and the rest are carbon atoms. Examples of heterocycles include but are not limited to morpholine, piperazine, piperidine, pyrrolidine, etc.
[0042] In the present invention, the "halogen atom" includes fluorine, chlorine, bromine and iodine atoms.
[0043] The term "substituted" as used herein means replacement by one or more groups. If it is not specified on a specific atom, it means that it can occur on any atom where the number of substituents has not yet reached saturation.
[0044] The term “independently” used in the present invention means that when a plurality of substituents are selected from the same series, they may be the same or different.
[0045] "Pharmaceutically acceptable salt" of the present invention can be a salt formed by an anion and a positively charged group on the compound of formula (I). Suitable anions are chloride, bromide, iodide, sulfate, nitrate, phosphate, citrate, methanesulfonate, trifluoroacetate, acetate, malate, toluenesulfonate, tartrate, fumarate, glutamate, glucuronide, lactate, glutarate or maleate. Similarly, salts can be formed by a cation and a negatively charged group on the compound of formula (I). Suitable cations include sodium, potassium, magnesium, calcium and ammonium ions, such as tetramethylammonium ions. Preferably, "pharmaceutically acceptable salts" refer to salts of the compound of formula (I) formed with an acid selected from the group consisting of hydrofluoric acid, hydrochloric acid, hydrobromic acid, phosphoric acid, acetic acid, oxalic acid, sulfuric acid, nitric acid, methanesulfonic acid, aminosulfonic acid, salicylic acid, trifluoromethanesulfonic acid, naphthalenesulfonic acid, maleic acid, citric acid, acetic acid, lactic acid, tartaric acid, succinic acid, oxalic acid, pyruvic acid, malic acid, glutamic acid, p-toluenesulfonic acid, naphthalenesulfonic acid, ethanesulfonic acid, naphthalenedisulfonic acid, malonic acid, fumaric acid, propionic acid, oxalic acid, trifluoroacetic acid, stearic acid, pamoic acid, hydroxymaleic acid, phenylacetic acid, benzoic acid, glutamic acid, ascorbic acid, p-aminobenzenesulfonic acid, 2-acetoxybenzoic acid and isethionic acid, etc.
[0046] The compound of the general formula (I) of the present invention or its pharmaceutically acceptable salt is separated out by distillation, crystallization or recrystallization from water or an organic solvent, and the compound may contain the solvent molecules used. In addition, different crystallization conditions may lead to different crystal forms of the compound. Therefore, the compound shown in the general formula (I) or its pharmaceutically acceptable salt containing different chemical doses of crystallization solvents and all crystal forms is within the scope of the present invention.
[0047] In the present invention, some compounds are asymmetric, for example, have one or more stereocenters, have olefinic bonds. Unless otherwise specified, the present invention is intended to include all stereo, optical and geometric isomers, such as but not limited to enantiomers, diastereomers, racemates, E / Z isomers, and mixtures of individual isomers in different proportions, and pharmaceutically acceptable salts thereof. The compounds of the present invention containing asymmetrically substituted carbon atoms can be separated in optically active, racemic or cis-trans isomeric forms.
[0048] In the present invention, the "effective therapeutic dose" means that the subjects receiving the treatment with the dose are cured, improved, effectively prevented, or the incidence of the disease or side effects is significantly reduced compared with the subjects who have not received the treatment with the dose; in addition, it also includes an effective dose that enhances normal physiological functions.
[0049] Another object of the present invention is to provide a method for preparing the compound represented by general formula (I), wherein the method is selected from route 1 or 2;
[0050] The reaction steps of route 1 are shown in formula A:
[0051]
[0052] Wherein, PG represents a hydroxyl protecting group, such as but not limited to tetrahydropyran (THP), tert-butyldimethylsilyl (TBDMS), 2-trimethylsilylethoxymethyl (SEM); halo is a halogen atom; and the other substituents are defined the same as those in the aforementioned general formula (I);
[0053] The reaction steps of route 1 include:
[0054] (1.1) Intermediate INT-A1 (synthesized by referring to WO2014143799) and alkyne raw materials (commercially purchased or synthesized according to literature methods) undergoes Sonogashira coupling reaction to generate intermediate INT-A2;
[0055] The Sonogashira coupling reaction is usually carried out under the action of a palladium catalyst, a copper salt and an organic base; the palladium catalyst is, for example, but not limited to, PdCl2(Ph3P)2, PdCl2(dppf), Pd(Ph3P)4; the copper salt is, for example, but not limited to, CuI, CuBr; the organic base is, for example, but not limited to, triethylamine, N,N-diisopropylethylamine (DIPEA); the reaction is carried out in an excess of an organic base or with the addition of an appropriate amount of an organic solvent, such as N,N-dimethylformamide (DMF); the reaction temperature is generally room temperature to 80°C; those skilled in the art may appropriately adjust the reaction conditions according to the literature or the actual situation encountered during the synthesis process;
[0056] (1.2) The intermediate INT-A2 is deprotected to generate a compound of the general formula (I); the deprotection reaction of the hydroxyl group is usually carried out under the action of an acidic reagent or a fluoride ion reagent; the acidic reagent is for example but not limited to trifluoroacetic acid, hydrogen chloride, p-toluenesulfonic acid; the fluoride ion reagent is for example but not limited to tetrabutylammonium fluoride, KF, HF;
[0057] (1.3) In another alternative, the hydroxyl protecting group of intermediate INT-A1 can be first removed to generate intermediate INT-A3, which can then be reacted with an acetylene raw material. A Sonogashira coupling reaction occurs to generate a compound of formula (I); the reaction conditions are the same as those in steps (1) and (2);
[0058] Reaction Scheme 2 is applicable to compounds of formula (II b) and (II c), and the reaction steps are shown in Formula B:
[0059]
[0060] Wherein, L is a leaving group, including sulfonate and halogen atom, such as but not limited to methanesulfonate, trifluoromethanesulfonate, p-toluenesulfonate, chlorine atom, bromine atom, iodine atom; PG and halo are defined the same as in the above formula A; the definitions of other substituents are the same as in the above general formulas (II b) and (II c);
[0061] The reaction steps of route 2 include:
[0062] (2.1) Intermediate INT-A1 (synthesized with reference to WO2014143799) and alkyne raw materials (commercially purchased or synthesized according to literature methods) undergoes Sonogashira coupling reaction to generate intermediate INT-B1; the reaction conditions are the same as those in the above reaction step (1.1);
[0063] (2.2) The intermediate INT-B1 undergoes a sulfonylation reaction or a halogenation reaction to generate the intermediate INT-B2; the sulfonylation reaction is carried out by a sulfonylating agent in the presence of a base; the sulfonylating agent includes, but is not limited to, methanesulfonyl chloride, trifluoromethanesulfonic anhydride, and p-toluenesulfonyl chloride; the base includes an organic base and an inorganic base, the organic base includes, but is not limited to, triethylamine, DIPEA, and p-dimethylaminopyridine (DMAP), and the inorganic base includes, but is not limited to, K2CO3 and Cs2CO3; the halogenation reaction is carried out in the presence of a halogenating agent; the halogenating agent includes, but is not limited to, thionyl chloride, phosphorus tribromide, I2 / Ph3P, etc.; the reaction solvent is usually an aprotic solvent, such as, but not limited to, dichloromethane and tetrahydrofuran; the reaction temperature is generally -20°C to room temperature;
[0064] (2.3) Intermediate INT-B2 and HOR 4 Substitution reaction occurs to generate intermediate INT-B3, or intermediate INT-B2 reacts with HN(R 4 )2 undergoes a substitution reaction to generate an intermediate INT-B4; the substitution reaction is carried out under the action of a base; the base includes an organic base and an inorganic base, an organic base such as but not limited to triethylamine, DIPEA, DMAP, an inorganic base such as but not limited to K2CO3, Cs2CO3, NaH; the reaction solvent is usually a polar solvent, such as but not limited to tetrahydrofuran, acetonitrile, DMF; the reaction temperature is generally 0°C to 80°C;
[0065] (2.4) Removing the protecting group from the intermediate INT-B3 or the intermediate INT-B4 to generate a compound of the general formula (II b) or the general formula (II c); the reaction conditions are the same as those in the aforementioned reaction step (1.2).
[0066] The present invention also discloses a use of the compound or a pharmaceutically acceptable salt thereof, wherein the compound or a pharmaceutically acceptable salt thereof is used as a TRPC4 and TRPC5 inhibitor, or is used to prepare a drug for treating diseases related to abnormal function or expression of TRPC4 or / and TRPC5.
[0067] In the present invention, the compound represented by the general formula (I), its salt and pharmaceutical composition thereof can be used in combination with drugs with other mechanisms of action when used to treat skin diseases; the drugs include, but are not limited to, glucocorticoid drugs, such as mometasone, fluocinolone, triamcinolone acetonide, hydrocortisone, clobetasol, etc.; Janus kinase inhibitors, such as ruxolitinib, tofacitinib, upadacitinib, etc.; calcineurin inhibitors, such as tacrolimus, pimecrolimus; biological immunomodulators, such as adalimumab, infliximab, etanercept, etc.
[0068] In the present invention, the compound represented by the general formula (I) is usually used to prepare a drug in the form of a pharmaceutical composition, which comprises one or more compounds of the general formula (I) in an effective therapeutic dose and one or more pharmaceutical excipients; the pharmaceutical excipients are pharmaceutically acceptable carriers, excipients, sustained-release agents, odorants, flavoring agents, etc.
[0069] In the pharmaceutical composition, the compound represented by general formula (I) is used as an active ingredient, and its weight accounts for 0.1 to 99.9% of the total weight of the pharmaceutical composition, and the rest are pharmaceutically acceptable excipients; the preferred ratio of the compound represented by general formula (I) to the pharmaceutically acceptable excipients is that the compound represented by general formula (I) as an active ingredient accounts for more than 60% of the total weight, and the rest accounts for 0-40% of the total weight, and the amount of the rest is preferably 1-20%, and most preferably 1-10%.
[0070] The compounds and pharmaceutical compositions provided by the present invention can be prepared into various dosage forms based on the conventional processes in the field of pharmaceutical preparations, such as tablets, capsules, powders, syrups, solutions, suspensions, sprays, creams, ointments, gels, transdermal patches, etc., and can be present in suitable solid or liquid carriers or diluents. The pharmaceutical compositions of the present invention can also be stored in suitable sterile apparatus for injection or infusion.
[0071] As a further improvement of the technical solution, the pharmaceutical composition is used to treat skin diseases associated with abnormal keratinocytes.
[0072] As a further improvement of the technical solution, the disease is psoriasis, ichthyosis, palmoplantar keratoderma, Olmsted's disease, toad skin disease or menopausal keratoderma.
[0073] The compound represented by the general formula (I) or the pharmaceutical composition comprising the compound represented by the general formula (I) can be used clinically in mammals, including humans and animals, and the administration route can include oral administration, nasal inhalation, topical administration to the skin, pulmonary administration or gastrointestinal tract, etc. The preferred administration route is topical administration to the skin. In the present invention, topical administration refers to applying the drug to the body surface, such as the skin or mucous membrane.
[0074] When the compound represented by the general formula (I) of the present invention or its pharmaceutical composition is used to prepare a topical drug for skin application, it can be made into a suitable pharmaceutical dosage form, such as but not limited to creams, ointments, gels, transdermal patches, sprays, etc. The drug carrier can be selected from starch, grease, cream, foam, ointment, skin lotion, gel, etc., or it can be a drug delivery system, such as liposomes, liposomes, microsponges, microemulsions, microspheres, solid lipid nanoparticles, etc.
[0075] When used as a pharmaceutical preparation, the compound shown in the general formula (I) of the present invention can be effectively dissolved, suspended or dispersed in a liquid medium to form a solution, suspension or dispersion, which can be applied to the skin by smearing or spraying, and can be delivered with the aid of a sponge, a patch, a cushion or other cosmetics. In some cases, the sustained-release delivery system of the compound may be very important for exerting the drug effect.
[0076] When used as a pharmaceutical preparation, the compound represented by the general formula (I) of the present invention is preferably in a unit dose, each dose containing 0.01 mg-200 mg of the active ingredient, preferably 0.5 mg-50 mg, for single or divided use. Regardless of the method of administration, the optimal dose for an individual should be determined according to the specific treatment. Usually, it is started with a small dose and gradually increased until the most suitable dose is found.
[0077] The present invention has outstanding substantive features and significant progress compared to the prior art. Specifically, the fused pyrimidine dione compounds and pharmaceutically acceptable salts thereof of the present invention can be used as TRPC4 / 5 inhibitors or prepared to treat skin diseases related to keratinocyte lesions. Furthermore, compared with existing TRPC4 / 5 inhibitors, the compounds disclosed in the present invention have higher in vitro activity and faster liver microsomal metabolism rate. Furthermore, when the compounds of the present invention are used to prepare topical drugs for skin use, they can be metabolized and cleared by the liver more quickly after being absorbed by the skin, avoiding systemic side effects. BRIEF DESCRIPTION OF THE DRAWINGS
[0078] Figure 1 This is a graph showing the effect of compound E37 in inhibiting IL-17-induced proliferation of human immortalized keratinocytes HaCaT and the quantitative results.
[0079] Figure 2This is a picture showing that a cream with compound E37 as the active ingredient improves the appearance symptoms of the mouse psoriasis model induced by imiquimod.
[0080] Figure 3 This is a graph showing the effect of a cream with compound E37 as the active ingredient in improving imiquimod-induced back skin disease in mice and the quantitative results. Specific embodiments
[0081] The present invention will be further described below with reference to examples. It should be particularly noted that these examples are only used to illustrate the present invention and are not intended to limit the present invention in any way. All parameters and other descriptions in the examples are based on mass unless otherwise specified. The fillers used for column chromatography separation are all silica gel unless otherwise specified. The experimental methods in the following examples that do not specify specific conditions are usually carried out under conventional conditions or under conditions recommended by the manufacturer.
[0082] Unless otherwise defined, all professional and scientific terms used herein have the same meanings as those familiar to those skilled in the art. In addition, any methods and materials similar or equivalent to those described herein may be applied to the present invention. The preferred implementation methods and materials described herein are for demonstration purposes only.
[0083] Abbreviations: DCM: dichloromethane; DIPEA: N,N-diisopropylethylamine; DMAP: 4-dimethylaminopyridine; DMF: N,N-dimethylformamide; DMSO: dimethyl sulfoxide; TBAF: tetrabutylammonium fluoride; TFA: trifluoroacetic acid; THF: tetrahydrofuran.
[0084] Example E1: 7-(4-chlorobenzyl)-1-(3-hydroxypropyl)-8-(3-methoxyprop-1-yn-1-yl)-3-methyl-3,7-dihydro-1H-purine-2,6-dione
[0085]
[0086] The raw material INT 1-1 was synthesized according to the method described in patent application WO2014143799. INT 1-1 (43 mg, 0.1 mmol), PdCl2 (Ph3P) 2 (10.5 mg, 0.015 mmol), CuI (5.7 mg, 0.03 mmol), 1.5 mL of triethylamine and 0.5 mL of DMF were placed in a pressure tube, degassed with nitrogen for 3 min, and then 3-methoxy-1-propyne (42 μL, 0.5 mmol) was added, and then degassed for 0.5 min. The pressure tube was sealed and heated at 60 ° C for 6 h. After cooling, it was diluted with ethyl acetate, the insoluble matter was removed by filtration, and the filtrate was evaporated to dryness under reduced pressure to obtain a crude product. It was then purified by a preparative liquid chromatography column (C18 filler), eluted with an acetonitrile / water system as the mobile phase, and the target product portion was collected and evaporated to dryness to obtain 20 mg of a white solid. 1 H-NMR(500MHz,Chloroform-d)δ7.41(d,J=8.5Hz,2H),7.34(d,J=8.5Hz,2H),5.59(s,2H),4.45(s,2H),4.20( t,J=4.0Hz,2H),3.60(s,3H),3.54(m,2H),3.49(s,3H),3.37(brs,1H),1.91(m,2H); MS(ESI):m / z417.1[M+H] + .
[0087] Example E2: 7-(4-chlorobenzyl)-8-(3-cyclobutoxyprop-1-yn-1-yl)-1-(3-hydroxypropyl)-3-methyl-3,7-dihydro-1H-purine-2,6-dione
[0088]
[0089] Sodium hydride (60% dispersed in oil, 1.44 g, 36 mmol) was suspended in 20 mL of dry THF, and cyclobutanol (2 g, 27.78 mmol) was added dropwise to generate gas. The mixture was dripped over 5 min and stirred for 0.5 h. Propylene bromide (2.63 mL, 30.5 mmol) was then added dropwise to the mixture. The mixture was dripped over 5 min and heated at 50 °C for 4 h. TLC showed that the raw material disappeared. After cooling, 2 mL of saturated ammonium chloride solution was added dropwise to quench the reaction, and anhydrous magnesium sulfate was added to dry the mixture. After 1 h, the inorganic salt was filtered off, washed with THF, and then THF was added to about 28 mL to obtain a THF solution of the intermediate INT 2-1 with a concentration of 1 mol / L.
[0090] The intermediate INT 2-2 was synthesized according to the method described in patent application WO2014143799.
[0091] INT 2-2 (102 mg, 0.2 mmol), PdCl2(Ph3P)2 (21 mg, 0.03 mmol), CuI (11.4 mg, 0.06 mmol), 3 mL of triethylamine and 1 mL of DMF were placed in a pressure tube and degassed with nitrogen for 3 min. Then, the intermediate INT2-1 (1 mL, 1 mmol) was added and degassed for another 1 min. The pressure tube was sealed and heated at 60 ° C for 4 h. After cooling, it was diluted with ethyl acetate, the insoluble matter was filtered out, and the filtrate was evaporated to dryness under reduced pressure to obtain a crude product. Then, it was separated by a flash silica gel column, eluted with MeOH / DCM as the mobile phase, and the target product was collected and evaporated to dryness to obtain 86 mg of a white solid, i.e., the intermediate INT 2-3.
[0092] The intermediate INT 2-3 (86 mg, 0.16 mmol) was dissolved in 2 mL DCM, and then 0.4 mL TFA was added and stirred at room temperature for 1 h. TLC showed that the reaction was complete. The solvent was evaporated under reduced pressure, and the residue was purified by a preparative liquid chromatography column (C18 filler) with acetonitrile / water system as the mobile phase. The target product was collected and evaporated to dryness to obtain 42 mg of a white solid, namely Example E2. 1 H-NMR(500MHz,Chloroform-d)δ7.40(d,J=8.5Hz,2H),7.33(d,J=8.5Hz,2H),5.59(s,2H),4.39(s,2H),4.20(t,J=4.0Hz,2 H),4.15(m,1H),3.59(s,3H),3.54(m,2H),3.33(brs,1H),2.26(m,2H),2.01(m,2H),1.76(m,1H),1.57(m,1H); MS(ESI):m / z 457.2[M+H] + .
[0093] Example E3: 7-(4-chlorobenzyl)-8-(3-cyclobutoxyprop-1-yn-1-yl)-1-(2-hydroxyethyl)-3-methyl-3,7-dihydro-1H-purine-2,6-dione
[0094]
[0095] 8-Bromo-3-methyl-3,7-dihydro-1H-purine-2,6-dione (244 mg, 1 mmol) was dissolved in 10 mL DMF, KHCO3 (150 mg, 1.5 mmol) and 4-chlorobenzyl bromide (204 mg, 1 mmol) were added, and the mixture was reacted at 60°C for 3 hours. After the reaction was completed by TLC, the insoluble matter was removed by filtration, and the organic phase was separated by partitioning with ethyl acetate / saturated NaCl aqueous solution, dried over anhydrous sodium sulfate, and separated by flash silica gel chromatography, eluted with MeOH / DCM as the mobile phase, and the target product, i.e., the intermediate INT 3-1, was collected, about 330 mg.
[0096] The above INT 3-1 (330 mg, 0.89 mmol) was dissolved in DMF, K2CO3 (249 mg, 1.8 mmol) was added, and then 2-(2-bromoethoxy)tetrahydro-2H-pyran (225 mg, 1.08 mmol) was added, and the mixture was reacted at 60°C for 6 hours. After cooling, the mixture was partitioned with ethyl acetate / saturated aqueous NaCl solution, the organic phase was separated, dried over anhydrous sodium sulfate, and separated by a flash silica gel chromatography column to obtain about 400 mg of the intermediate INT 3-2.
[0097] The synthesis method of intermediate INT 3-3 is the same as INT 2-3, except that intermediate INT 3-2 is used as the starting material instead of INT 2-2.
[0098] The synthesis method of Example E3 is the same as that of E2, except that the intermediate INT 3-3 is used as the starting material instead of INT 2-3.
[0099] H-NMR(500MHz,DMSO-d6)δ7.50–7.41(m,2H),7.36–7.30(m,2H),5.57(s,2H) ,4.76(t,J=6.0Hz,1H),4.40(s,2H),4.04–3.98(m,1H),3.96(t,J=6.5Hz,2H) ,3.52(q,J=6.5Hz,2H),3.41(s,3H),2.16–2.07(m,2H),1.84(ttd,J=10.0,7 .9,2.8Hz,2H),1.68–1.58(m,1H),1.45(qt,J=10.5,8.0Hz,1H).MS(ESI):m / z 443.1[M+H] + .
[0100] Example E4: 7-(4-chlorobenzyl)-8-(3-cyclobutoxyprop-1-yn-1-yl)-1-(4-hydroxybutyl)-3-methyl-3,7-dihydro-1H-purine-2,6-dione
[0101]
[0102] The synthesis method of intermediate INT 4-1 is the same as INT 3-2, except that (4-bromobutoxy)(tert-butyl)dimethylsilane is used instead of 2-(2-bromoethoxy)tetrahydro-2H-pyran as the starting material.
[0103] The synthesis method of intermediate INT 4-2 is the same as INT 2-3, except that intermediate INT 4-1 is used as the starting material instead of INT 2-2.
[0104] The intermediate INT 4-2 (117 mg, 0.2 mmol) was dissolved in 8 mL THF, and then a 1 mol / L TBAF tetrahydrofuran solution was added dropwise at room temperature, and stirred at room temperature for 1 h. TLC showed that the reaction was complete. The mixture was quenched with a saturated NH4Cl aqueous solution, extracted twice with ethyl acetate, washed once with a saturated NaCl aqueous solution, and dried over anhydrous magnesium sulfate. The crude product was filtered and evaporated to dryness, and then purified by a preparative liquid chromatography column (C18 filler), eluted with an acetonitrile / water system as the mobile phase, and the target product was collected and evaporated to dryness to obtain 55 mg of a white solid, i.e., Example E4. 1 H-NMR(600MHz,DMSO-d6)δ7.43(d,J=8.4Hz,2H),7.31(d,J=8.4Hz,2H),5.56(s,2H) ,4.39(s,2H),4.38(t,J=5.7Hz,1H),3.99(p,J=7.3Hz,1H),3.86(t,J=7.4Hz,2H),3. 42–3.36(m,5H),2.10(dtt,J=9.4,7.2,2.6Hz,2H),1.84(dtd,J=12.5,10.0,7.9Hz, 2H),1.66–1.59(m,1H),1.55(td,J=8.1,5.7Hz,2H),1.45–1.37(m,3H).MS(ESI):m / z 471.2[M+H] + .
[0105] Example E5: 8-(3-cyclobutoxyprop-1-yn-1-yl)-7-(4-fluorobenzyl)-1-(2-hydroxyethyl)-3-methyl-3,7-dihydro-1H-purine-2,6-dione
[0106]
[0107] The synthesis method of intermediate INT 5-1 is the same as INT 3-1, except that 4-fluorobenzyl bromide is used instead of 4-chlorobenzyl bromide as the starting material.
[0108] The synthesis method of intermediate INT 5-2 is the same as that of INT 3-2, except that intermediate INT 5-1 is used as the starting material instead of INT 3-1.
[0109] The synthesis method of intermediate INT 5-3 is the same as INT 2-3, except that intermediate INT 5-2 is used as the starting material instead of INT 2-2.
[0110] The synthesis method of Example E5 is the same as that of E2, except that the intermediate INT 5-3 is used as the starting material instead of INT 2-3. 1 H-NMR(500MHz,DMSO-d6)δ7.42–7.35(m,2H),7.24–7.17(m,2H),5.56(s,2H),4.76( t,J=6.0Hz,1H),4.42(s,2H),4.08–4.00(m,1H),3.97(t,J=6.6Hz,2H),3.52(q,J=6. 5Hz,2H),3.41(s,3H),2.13(dddd,J=10.6,6.8,5.2,2.5Hz,2H),1.86(dddd,J=19.3, 10.0,7.9,2.8Hz,2H),1.69–1.58(m,1H),1.45(qt,J=10.5,8.0Hz,1H).MS(ESI):m / z 427.2[M+H] + .
[0111] Example E6: 8-(3-cyclobutoxyprop-1-yn-1-yl)-7-(4-fluorobenzyl)-1-(3-hydroxypropyl)-3-methyl-3,7-dihydro-1H-purine-2,6-dione
[0112]
[0113] The synthesis method of intermediate INT 6-1 is the same as INT 3-2, except that intermediate INT 5-1 is used instead of INT 3-1, and 2-(3-bromopropoxy)tetrahydro-2H-pyran is used instead of 2-(2-bromoethoxy)tetrahydro-2H-pyran as the starting material.
[0114] The synthesis method of intermediate INT 6-2 is the same as INT 2-3, except that intermediate INT 6-1 is used as the starting material instead of INT 2-2.
[0115] The synthesis method of Example E6 is the same as that of E2, except that the intermediate INT 6-2 is used as the starting material instead of INT 2-3. 1H-NMR (500MHz, DMSO-d6) δ7.360~7.387(m,2H),7.178~7.213(m,2H),5.546(s, 2H),4.447~4.467(t,J=5Hz,1H),4.408(s,2H),3.997~4.055(m,1H),3.902~3.9 32(t,J=7Hz,2H),3.413~3.449(q,J=6Hz,2H),3.397(s,3H),2.093~2.150(m,2H ),1.810~1.869(m,2H),1.671~1.712(m,2H),1.414~1.468(m,2H).MS(ESI):m / z 441.2[M+H] + .
[0116] Example E7: 8-(3-cyclobutoxyprop-1-yn-1-yl)-7-(4-fluorobenzyl)-1-(4-hydroxybutyl)-3-methyl-3,7-dihydro-1H-purine-2,6-dione
[0117]
[0118] The synthesis method of intermediate INT 7-1 is the same as INT 3-2, except that intermediate INT 5-1 is used instead of INT 3-1, and (4-bromobutoxy)(tert-butyl)dimethylsilane is used instead of 2-(2-bromoethoxy)tetrahydro-2H-pyran as the starting material.
[0119] The synthesis method of intermediate INT 7-2 is the same as INT 2-3, except that intermediate INT 7-1 is used as the starting material instead of INT 2-2.
[0120] The synthesis method of Example E7 is the same as that of E4, except that the intermediate INT 7-2 is used as the starting material instead of INT 4-2. 1 H-NMR(600MHz,DMSO-d6)δ7.40–7.32(m,2H),7.19(t,J=8.8Hz,2H),5.55(s,2H), 4.41(s,2H),4.38(t,J=5.2Hz,1H),4.03(p,J=7.3Hz,1H),3.86(t,J=7.4Hz,2H), 3.39(m,5H),2.12(dddd,J=11.1,9.4,6.9,2.5Hz,2H),1.85(dtd,J=12.5,10.2,8 .0Hz,2H),1.66–1.59(m,1H),1.59–1.52(m,2H),1.47–1.37(m,3H).MS(ESI):m / z 455.2[M+H] + .
[0121] Example E8: 8-(3-cyclobutoxyprop-1-yn-1-yl)-7-(3,4-difluorobenzyl)-1-(2-hydroxyethyl)-3-methyl-3,7-dihydro-1H-purine-2,6-dione
[0122]
[0123] The synthesis method of intermediate INT 8-1 is the same as INT 3-1, except that 3,4-difluorobenzyl bromide is used instead of 4-chlorobenzyl bromide as the starting material.
[0124] The synthesis method of intermediate INT 8-2 is the same as INT 3-2, except that intermediate INT 8-1 is used as the starting material instead of INT 3-1.
[0125] The synthesis method of intermediate INT 8-3 is the same as INT 2-3, except that intermediate INT 8-2 is used as the starting material instead of INT 2-2.
[0126] The synthesis method of Example E8 is the same as that of E2, except that the intermediate INT 8-3 is used as the starting material instead of INT 2-3. 1 H-NMR(600MHz,DMSO-d6)δ7.48–7.37(m,2H),7.18–7.11(m,1H),5.56(s,2H), 4.74(t,J=6.0Hz,1H),4.40(s,2H),4.05–3.99(m,1H),3.96(t,J=6.6Hz,2H),3 .52(q,J=6.5Hz,2H),3.40(s,3H),2.12(dtt,J=11.5,6.9,2.5Hz,2H),1.84(tt d,J=10.0,7.8,2.8Hz,2H),1.67–1.58(m,1H),1.48–1.41(m,1H).MS(ESI):m / z 445.2[M+H] + .
[0127] Example E9: 8-(3-cyclobutoxyprop-1-yn-1-yl)-7-(3,4-difluorobenzyl)-1-(3-hydroxypropyl)-3-methyl-3,7-dihydro-1H-purine-2,6-dione
[0128]
[0129] The synthesis method of intermediate INT 9-1 is the same as INT 3-2, except that intermediate INT 8-1 is used instead of INT 3-1, and 2-(3-bromopropoxy)tetrahydro-2H-pyran is used instead of 2-(2-bromoethoxy)tetrahydro-2H-pyran as the starting material.
[0130] The synthesis method of intermediate INT 9-2 is the same as INT 2-3, except that intermediate INT 9-1 is used as the starting material instead of INT 2-2.
[0131] The synthesis method of Example E9 is the same as that of E2, except that the intermediate INT 9-2 is used as the starting material instead of INT 2-3. 1 H-NMR (600MHz, DMSO-d6) δ7.48–7.37(m,2H),7.14(m,1H),5.55(s,2H),4.45(t,J=5.3Hz,1H),4.40(s,2H),4.01(p,J=7.2Hz,1H),3. 92(t,J=6.0,H),3.43(q,J=6.1Hz,2H),3.40(s,3H),2.15–2.08(m,2H),1.84(m,2H),1.72–1.66(m,2H),1.66–1.58(m,1H),1.44(m,J 1H); MS(ESI):m / z 459.2[M+H] + .
[0132] Example E10: 8-(3-cyclobutoxyprop-1-yn-1-yl)-7-(3,4-difluorobenzyl)-1-(4-hydroxybutyl)-3-methyl-3,7-dihydro-1H-purine-2,6-dione
[0133]
[0134] The synthesis method of intermediate INT 10-1 is the same as INT 3-2, except that intermediate INT 8-1 is used instead of INT 3-1, and (4-bromobutoxy)(tert-butyl)dimethylsilane is used instead of 2-(2-bromoethoxy)tetrahydro-2H-pyran as the starting material.
[0135] The synthesis method of intermediate INT 10-2 is the same as INT 2-3, except that intermediate INT 10-1 is used as the starting material instead of INT 2-2.
[0136] The synthesis method of Example E10 is the same as that of E4, except that the intermediate INT 10-2 is used as the starting material instead of INT 4-2. 1H-NMR(600MHz,DMSO-d6)δ7.47–7.37(m,2H),7.14(ddd,J=9.8,4.6,2.2Hz,1H) ,5.55(s,2H),4.40(s,2H),4.38(t,J=5.2Hz,1H),4.01(p,J=7.3Hz,1H),3.87(t ,J=7.4Hz,2H),3.42–3.36(m,5H),2.11(ddt,J=14.7,6.9,2.5Hz,2H),1.89–1.8 0(m,2H),1.66–1.60(m,1H),1.59–1.53(m,2H),1.47–1.38(m,3H).MS(ESI):m / z 473.2[M+H] + .
[0137] Example E11: 7-(4-chloro-2-fluorobenzyl)-8-(3-cyclobutoxyprop-1-yn-1-yl)-1-(2-hydroxyethyl)-3-methyl-3,7-dihydro-1H-purine-2,6-dione
[0138]
[0139] The synthesis method of intermediate INT 11-1 is the same as INT3-1, except that 4-chloro-2-fluorobenzyl bromide is used instead of 4-chlorobenzyl bromide as the starting material.
[0140] The synthesis method of intermediate INT 11-2 is the same as INT 3-2, except that intermediate INT 11-1 is used as the starting material instead of INT 3-1.
[0141] The synthesis method of intermediate INT 11-3 is the same as INT 2-3, except that intermediate INT 11-2 is used as the starting material instead of INT 2-2.
[0142] The synthesis method of Example E11 is the same as that of E2, except that the intermediate INT 11-3 is used as the starting material instead of INT 2-3. 1H-NMR(600MHz,DMSO-d6)δ7.52(dd,J=10.1,2.0Hz,1H),7.26(dd,J=8.3,2.0Hz,1H),7.09( t,J=8.2Hz,1H),5.61(s,2H),4.73(t,J=5.9Hz,1H),4.34(s,2H),3.95(m,3H),3.49(q,J=6 .4Hz,2H),3.41(s,3H),2.08(dtd,J=11.7,7.5,6.2,2.6Hz,2H),1.82(dq,J=13.2,10.1Hz, 2H),1.61(q,J=10.1Hz,1H),1.43(dtd,J=18.5,10.5,8.1Hz,1H).MS(ESI):m / z461.1[M+H] + .
[0143] Example E12: 7-(4-chloro-2-fluorobenzyl)-8-(3-cyclobutoxyprop-1-yn-1-yl)-1-(3-hydroxypropyl)-3-methyl-3,7-dihydro-1H-purine-2,6-dione
[0144]
[0145] The synthesis method of intermediate INT 12-1 is the same as INT3-2, except that intermediate INT 11-1 is used instead of INT 3-1, and 2-(3-bromopropoxy)tetrahydro-2H-pyran is used instead of 2-(2-bromoethoxy)tetrahydro-2H-pyran as the starting material.
[0146] INT 12-1 (100 mg, 0.1894 mmol), PdCl2(Ph3P)2 (19.9 mg, 0.0284 mmol), CuI (10.8 mg, 0.0568 mmol), 3 mL of triethylamine and 1 mL of DMF were placed in a pressure tube, degassed with nitrogen for 3 min, and then the intermediate INT2-1 (0.95 mL, 0.95 mmol) was added, and then degassed for another 1 min. The pressure tube was sealed and heated at 60 ° C for 4 h. After cooling, it was diluted with ethyl acetate, the insoluble matter was filtered out, and the filtrate was evaporated to dryness under reduced pressure to obtain a crude product. Then it was separated by a flash silica gel column, eluted with MeOH / DCM as the mobile phase, and the target product was collected and evaporated to dryness to obtain 86 mg of a white solid, i.e., the intermediate INT12-2.
[0147] The intermediate INT12-2 (84 mg, 0.15 mmol) was dissolved in 2 mL DCM, and then 0.4 mL TFA was added and stirred at room temperature for 1 h. TLC showed that the reaction was complete. The solvent was evaporated under reduced pressure, and the residue was purified by preparative liquid chromatography column with acetonitrile / water system as mobile phase for elution. The target product was collected and evaporated to dryness to obtain 41 mg of white solid, i.e. Example E12. 1 H-NMR(600MHz,DMSO-d6)δ7.52(dd,J=10.1,2.1Hz,1H),7.26(dd,J=8.2,2.1Hz,1H),7.0 9(t,J=8.3Hz,1H),5.61(s,2H),4.44(t,J=5.2Hz,1H),4.34(s,2H),3.96(p,J=7.3Hz,1H) ,3.89(m,t,J=6.5Hz,2H),3.41(m,5H),2.12–2.04(m,2H),1.82(dtd,J=12.7,10.2,7.9H z,2H),1.67(p,J=6.5Hz,2H),1.63–1.57(m,1H),1.43(qt,J=10.5,8.0Hz,1H); (ESI):m / z 475.2[M+H] + .
[0148] Example E13: 7-(4-chloro-2-fluorobenzyl)-8-(3-cyclobutoxyprop-1-yn-1-yl)-1-(4-hydroxybutyl)-3-methyl-3,7-dihydro-1H-purine-2,6-dione
[0149]
[0150] The synthesis method of intermediate INT 13-1 is the same as INT 3-2, except that intermediate INT 11-1 is used instead of INT3-1, and (4-bromobutoxy)(tert-butyl)dimethylsilane is used instead of 2-(2-bromoethoxy)tetrahydro-2H-pyran as the starting material.
[0151] INT 13-1 (100 mg, 0.175 mmol), PdCl2(Ph3P)2 (18.4 mg, 0.0263 mmol), CuI (10 mg, 0.0526 mmol), 3 mL of triethylamine and 1 mL of DMF were placed in a pressure tube, degassed with nitrogen for 3 min, and then the intermediate INT2-1 (0.9 mL, 0.9 mmol) was added, and then degassed for another 1 min. The pressure tube was sealed and heated at 60 ° C for 4 h. After cooling, it was diluted with ethyl acetate, the insoluble matter was filtered out, and the filtrate was evaporated to dryness under reduced pressure to obtain a crude product. Then it was separated by a flash silica gel column, eluted with MeOH / DCM as the mobile phase, and the target product was collected and evaporated to dryness to obtain 90 mg of a white solid, i.e., the intermediate INT13-2.
[0152] The synthesis method of Example E13 is the same as that of E4, except that the intermediate INT 13-2 is used as the starting material instead of INT 4-2. 53 mg of Example E13 is obtained from 90 mg of the intermediate INT13-2 as a white solid. 1 H-NMR (600MHz, DMSO-d6) δ7.51(dd,J=10.1,2.1Hz,1H),7.26(dd,J=8.4,2.1Hz,1H),7.08(t,J=8.3Hz ,1H),5.61(s,2H),4.38(t,J=5.2Hz,1H),4.34(s,2H),4.00–3.92(m,1H),3.84(t,J=7.4Hz,2H),3.42 (s,3H),3.38(td,J=6.4,5.0Hz,2H),2.08(ddt,J=14.6,6.8,2.5Hz,2H),1.81(qdd,J=10.2,5.0,2.2H z,2H),1.65–1.58(m,1H),1.57–1.50(m,2H),1.41(dddd,J=21.9,15.8,11.8,7.3Hz,3H).MS(ESI):m / z 489.2[M+H] + .
[0153] Example E14: 7-(4-chloro-3-fluorobenzyl)-8-(3-cyclobutoxyprop-1-yn-1-yl)-1-(2-hydroxyethyl)-3-methyl-3,7-dihydro-1H-purine-2,6-dione
[0154]
[0155] The synthesis method of intermediate INT 14-1 is the same as INT3-1, except that 4-chloro-3-fluorobenzyl bromide is used instead of 4-chlorobenzyl bromide as the starting material.
[0156] The synthesis method of intermediate INT 14-2 is the same as INT 3-2, except that intermediate INT 14-1 is used as the starting material instead of INT 3-1.
[0157] The synthesis method of intermediate INT 14-3 is the same as INT 2-3, except that intermediate INT 14-2 is used as the starting material instead of INT 2-2.
[0158] The synthesis method of Example E14 is the same as that of E2, except that the intermediate INT 14-3 is used as the starting material instead of INT 2-3. 1 H-NMR(600MHz,DMSO-d6)δ7.59(t,J=8.0Hz,1H),7.36(dd,J=10.0,2.0Hz,1H) ,7.12(d,J=8.4Hz,1H),5.58(s,2H),4.73(t,J=6.0Hz,1H),4.38(s,2H),3.96 (m,3H),3.51(q,J=6.5Hz,2H),3.41(s,3H),2.13–2.05(m,2H),1.87–1.78(m, 2H),1.61(q,J=10.3Hz,1H),1.43(dtd,J=18.4,10.4,7.9Hz,1H).MS(ESI):m / z 461.1[M+H] + .
[0159] Example E15: 7-(4-chloro-3-fluorobenzyl)-8-(3-cyclobutoxyprop-1-yn-1-yl)-1-(3-hydroxypropyl)-3-methyl-3,7-dihydro-1H-purine-2,6-dione
[0160]
[0161] The synthesis method of intermediate INT 15-1 is the same as INT 3-2, except that intermediate INT 14-1 is used instead of INT 3-1, and 2-(3-bromopropoxy)tetrahydro-2H-pyran is used instead of 2-(2-bromoethoxy)tetrahydro-2H-pyran as the starting material.
[0162] INT 15-1 (100 mg, 0.1893 mmol), PdCl2(Ph3P)2 (19.9 mg, 0.0284 mmol), CuI (10.8 mg, 0.0568 mmol), 3 mL of triethylamine and 1 mL of DMF were placed in a pressure tube, degassed with nitrogen for 3 min, and then the intermediate INT2-1 (0.95 mL, 0.95 mmol) was added, and then degassed for another 1 min. The pressure tube was sealed and heated at 60 ° C for 4 h. After cooling, it was diluted with ethyl acetate, the insoluble matter was filtered out, and the filtrate was evaporated to dryness under reduced pressure to obtain a crude product. Then it was separated by a flash silica gel column, eluted with MeOH / DCM as the mobile phase, and the target product was collected and evaporated to dryness to obtain 81 mg of a white solid, i.e., the intermediate INT15-2.
[0163] The intermediate INT15-2 (81 mg, 0.145 mmol) was dissolved in 2 mL DCM, and then 0.4 mL TFA was added and stirred at room temperature for 1 h. TLC showed that the reaction was complete. The solvent was evaporated under reduced pressure, and the residue was purified by preparative liquid chromatography column with acetonitrile / water system as mobile phase for elution. The target product was collected and evaporated to dryness to obtain 39 mg of white solid, i.e. Example E15. 1 H-NMR(500MHz,Chloroform-d)δ7.40(t,J=8.0Hz,1H),7.26(d,J=9.4Hz,1H),7.22(d,J=8.4Hz,1H),5.58(s,2H),4.39(s,2H),4.21(t,J=6.0Hz,2H),4.15 (t,J=7.3Hz,1H),3.60(s,3H),3.56(t,J=5.5Hz,2H),2.26(t,J=7.8Hz,3H), 2.05–2.00(m,2H),1.93(m,2H),1.67(m,1H),1.61–1.52(m,1H).MS(ESI):m / z 475.2[M+H] + .
[0164] Example E16: 7-(4-chlorobenzyl)-8-(3-cyclobutoxyprop-1-yn-1-yl)-1-(3-hydroxypropyl)-3-isopropyl-3,7-dihydro-1H-purine-2,6-dione
[0165]
[0166] 2,6-Dihydroxypurine (15 g, 0.0987 mol) was suspended in 240 mL of water, and 7.5 mL of liquid bromine (0.1464 mol) was added dropwise at room temperature. After the addition was complete, the mixture was reacted at 100°C overnight. After cooling to room temperature, the solid was filtered, washed with distilled water several times, and dried to obtain the intermediate INT 16-1.
[0167] The intermediate INT 16-1 (2.3 g, 10 mmol) was dissolved in DMSO, KHCO3 (1.2 g, 12 mmol) was added, and then 4-chlorobenzyl bromide (2.04 g, 10 mmol) was added, and the reaction was continued at 35°C overnight. The reaction solution was poured into a saturated aqueous NaCl solution, extracted with ethyl acetate three times, the organic phases were combined, and then washed with a saturated aqueous NaCl solution three times. After drying over anhydrous MgSO4, the mixture was separated by a rapid silica gel column, and MeOH / DCM was used as the mobile phase for elution, and the target product was collected to obtain the intermediate INT 16-2.
[0168] The intermediate INT 16-2 (2.48 g, 7 mmol) was dissolved in DMF, K2CO3 (1.16 g, 8.4 mmol) and isopropyl iodide (1.19 g, 7 mmol) were added, and the mixture was reacted at 40°C overnight. The reaction solution was poured into a saturated aqueous NaCl solution, extracted 3 times with ethyl acetate, the organic phases were combined, and then washed 3 times with a saturated aqueous NaCl solution. After drying over anhydrous MgSO4, the mixture was separated by a rapid silica gel chromatography column, and MeOH / DCM was used as the mobile phase for elution. The target product was collected to obtain the intermediate INT 16-3.
[0169] The intermediate INT 16-3 (1.386 g, 3.5 mmol) was dissolved in DMF, K2CO3 (0.967 g, 7 mmol) and 2-(3-bromopropoxy)tetrahydro-2H-pyran (0.932 g, 4.2 mmol) were added, and the reaction was continued at 60°C overnight. The reaction solution was then poured into a saturated aqueous NaCl solution, extracted 3 times with ethyl acetate, the organic phases were combined, and then washed 3 times with a saturated aqueous NaCl solution. After drying over anhydrous MgSO4, the mixture was separated by a rapid silica gel chromatography column, and MeOH / DCM was used as the mobile phase for elution, and the target product was collected to obtain the intermediate INT16-4.
[0170] INT 16-4 (108 mg, 0.2 mmol), PdCl2(Ph3P)2 (21 mg, 0.03 mmol), CuI (11.4 mg, 0.06 mmol), 3 mL of triethylamine and 1 mL of DMF were placed in a pressure tube, degassed with nitrogen for 3 min, and then the intermediate INT2-1 (1 mL, 1 mmol) was added and degassed for another 1 min. The pressure tube was sealed and heated at 60 ° C for 4 h. After cooling, it was diluted with ethyl acetate, the insoluble matter was filtered out, and the filtrate was evaporated to dryness under reduced pressure to obtain a crude product. Then it was separated by a fast silica gel column, eluted with MeOH / DCM as the mobile phase, and the target product was collected and evaporated to dryness to obtain 80 mg of a white solid, i.e., the intermediate INT16-5.
[0171] The intermediate INT16-5 (80 mg, 0.14 mmol) was dissolved in 2 mL DCM, and then 0.4 mL TFA was added and stirred at room temperature for 1 h. TLC showed that the reaction was complete. The solvent was evaporated under reduced pressure, and the residue was purified by preparative liquid chromatography column with acetonitrile / water system as mobile phase for elution. The target product was collected and evaporated to dryness to obtain 40 mg of white solid, i.e. Example E16. 1 H-NMR(500MHz,DMSO-d6)δ7.48–7.42(m,2H),7.37–7.32(m,2H),5.57(s,2H ),5.05(m,1H),4.47(t,J=5.2Hz,1H),4.41(s,2H),4.00(m,1H),3.92(t,J=7 .5Hz,2H),3.44(q,J=6.1Hz,2H),2.17–2.07(m,2H),1.85(m,2H),1.69(m,2H ),1.65–1.59(m,1H),1.49(d,J=7.0Hz,6H),1.47–1.39(m,1H); MS(ESI):m / z 485.2[M+H] + .
[0172] Example E17: 7-(4-chlorobenzyl)-8-(3-cyclobutoxyprop-1-yn-1-yl)-3-ethyl-1-(3-hydroxypropyl)-3,7-dihydro-1H-purine-2,6-dione
[0173]
[0174] The synthesis method of intermediate INT 17-1 is the same as INT 16-3, except that iodoethane is used as the starting material instead of isopropyl iodide.
[0175] The synthesis method of intermediate INT 17-2 is the same as INT 16-4, except that intermediate INT 17-1 is used as the starting material instead of INT 16-3.
[0176] The synthesis method of intermediate INT 17-3 is the same as INT 16-5, except that intermediate INT 17-2 is used as the starting material instead of INT 16-4.
[0177] The synthesis method of Example E17 is the same as that of E16, except that the intermediate INT 17-3 is used as the starting material instead of INT 16-5. 1H-NMR(500MHz,DMSO-d6)δ7.44(d,J=8.4Hz,2H),7.34(d,J=8.2Hz,2H),5.5 7(s,2H),4.48(t,J=5.2Hz,1H),4.40(s,2H),4.12(q,J=5.2Hz,1H),4.01(m, 2H),3.93(t,J=7.0Hz,2H),3.44(q,J=6.1Hz,2H),2.12(m,2H),1.84(m,2H) ,1.69(m,2H),1.62(m,1H),1.45(m,1H),1.22(t,J=7.6Hz,3H); MS(ESI):m / z 471.2[M+H] +.
[0178] Example E18: 7-(4-chlorobenzyl)-8-(3-(cyclopentyloxy)prop-1-yn-1-yl)-1-(3-hydroxypropyl)-3-methyl-3,7-dihydro-1H-purine-2,6-dione
[0179]
[0180] Sodium hydride (60% dispersed in oil, 1.44 g, 36 mmol) was suspended in 20 mL of dry THF, and cyclopentanol (2.41 g, 28 mmol) was added dropwise to generate gas. The mixture was dripped over 5 min and stirred for 0.5 h. Propylene bromide (2.63 mL, 30.5 mmol) was then added dropwise to the mixture. The mixture was dripped over 5 min and heated at 50 °C for 4 h. TLC showed that the starting material disappeared. After cooling, 2 mL of saturated ammonium chloride solution was added dropwise to quench the reaction, and anhydrous magnesium sulfate was added to dry the mixture. After 1 h, the inorganic salt was filtered off, washed with THF, and then THF was added to about 28 mL to obtain a 1 mol / L THF solution of the intermediate INT 18-1.
[0181] INT 2-2 (100 mg, 0.196 mmol), PdCl2(Ph3P)2 (20.6 mg, 0.0294 mmol), CuI (11.17 mg, 0.0588 mmol), 3 mL of triethylamine and 1 mL of DMF were placed in a pressure tube and degassed with nitrogen for 3 min. Then, the intermediate INT18-1 (1 mL, 1 mmol) was added and degassed for another 1 min. The pressure tube was sealed and heated at 60°C for 4 to 6 h. After cooling, it was diluted with ethyl acetate, the insoluble matter was filtered out, and the filtrate was evaporated to dryness under reduced pressure to obtain a crude product. Then, it was separated by a fast silica gel column, eluted with MeOH / DCM as the mobile phase, and the target product was collected and evaporated to dryness to obtain 78 mg of a white solid, namely the intermediate INT 18-2.
[0182] The intermediate INT 18-2 (78 mg, 0.14 mmol) was dissolved in 2 mL DCM, and then 0.4 mL TFA was added and stirred at room temperature for 1 h. TLC showed that the reaction was complete. The solvent was evaporated under reduced pressure, and the residue was purified by preparative liquid chromatography column with acetonitrile / water system as mobile phase for elution. The target product was collected and evaporated to dryness to obtain 32 mg of white solid, i.e. Example E18. 1 H-NMR (500MHz, DMSO-d6) δ7.43(d,J=8.5Hz,2H),7.32(d,J=8.2Hz,2H),5.57(s,2H),4.48(t,J=5.2Hz,1H),4.45(s,2 H),4.02(m,1H),3.92(t,J=7.5Hz,2H),3.48–3.42(m,2H),3.41(s,3H),1.74–1.51(m,8H),1.47(m,2H); MS(ESI):m / z 471.2[M+H] + .
[0183] Example E19: 8-(3-(Cyclopentyloxy)prop-1-yn-1-yl)-7-(4-fluorobenzyl)-1-(3-hydroxypropyl)-3-methyl-3,7-dihydro-1H-purine-2,6-dione
[0184]
[0185] The synthesis method of Example E19 is the same as that of E18, except that the intermediate INT 6-1 is used as the starting material instead of INT 2-2. 1 H-NMR (500MHz, DMSO-d6) δ7.42–7.36(m,2H),7.23–7.16(m,2H),5.56(s,2H),4.47(m,3H),4.05(tt,J=5.8,2. 9Hz,1H),3.96–3.90(m,2H),3.44(q,J=6.2Hz,2H),3.41(s,3H),1.74–1.54(m,8H),1.49(m,2H); MS(ESI):m / z 455.2[M+H] + .
[0186] Example E20: 7-(4-chlorobenzyl)-8-(3-(cyclohexyloxy)prop-1-yn-1-yl)-1-(3-hydroxypropyl)-3-methyl-3,7-dihydro-1H-purine-2,6-dione
[0187]
[0188] Sodium hydride (60% dispersed in oil, 1.44 g, 36 mmol) was suspended in 20 mL of dry THF, and cyclohexanol (2.8 g, 27.78 mmol) was added dropwise to generate gas. The mixture was dripped over 5 min and stirred for 0.5 h. Propylene bromide (2.63 mL, 30.5 mmol) was then added dropwise to the mixture. The mixture was dripped over 5 min and heated at 50 °C for 4 h. TLC showed that the raw material disappeared. After cooling, 2 mL of saturated ammonium chloride solution was added dropwise to quench the reaction, and anhydrous magnesium sulfate was added to dry the mixture. After 1 h, the inorganic salt was filtered off, washed with THF, and then THF was added to about 28 mL to obtain a THF solution of the intermediate INT 20-1 with a concentration of 1 mol / L.
[0189] INT 2-2 (100 mg, 0.196 mmol), PdCl2(Ph3P)2 (20.6 mg, 0.0294 mmol), CuI (11.2 mg, 0.0588 mmol), 3 mL of triethylamine and 1 mL of DMF were placed in a pressure tube and degassed with nitrogen for 3 min. Then, the intermediate INT20-1 (1 mL, 1 mmol) was added and degassed for another 1 min. The pressure tube was sealed and heated at 60°C for 4 to 6 h. After cooling, it was diluted with ethyl acetate, the insoluble matter was filtered out, and the filtrate was evaporated to dryness under reduced pressure to obtain a crude product. Then, it was separated by a flash silica gel column, eluted with MeOH / DCM as the mobile phase, and the target product was collected and evaporated to dryness to obtain 66 mg of a white solid, namely the intermediate INT 20-2.
[0190] The intermediate INT 20-2 (66 mg, 0.12 mmol) was dissolved in 2 mL DCM, and then 0.4 mL TFA was added and stirred at room temperature for 1 h. TLC showed that the reaction was complete. The solvent was evaporated under reduced pressure, and the residue was purified by preparative liquid chromatography column with acetonitrile / water system as mobile phase for elution. The target product was collected and evaporated to dryness to obtain 30 mg of white solid, namely Example E20. 1 H-NMR (500MHz, DMSO-d6) δ7.43(d,J=8.3Hz,2H),7.32(d,J=8.2Hz,2H),5.56(s,2H),4.52(s,2H),4.47(t,J=5.2Hz,1H),3. 92(t,J=7.4Hz,2H),3.48–3.36(m,6H),1.82(m,2H),1.72–1.65(m,2H),1.63(m,2H),1.46(m,1H),1.20(m,5H).MS(ESI):m / z 485.2[M+H] + .
[0191] Example E21: 8-(3-(Cyclohexyloxy)prop-1-yn-1-yl)-7-(4-fluorobenzyl)-1-(3-hydroxypropyl)-3-methyl-3,7-dihydro-1H-purine-2,6-dione
[0192]
[0193] The synthesis method of Example E21 is the same as that of Example E20, except that the intermediate INT 6-1 is used as the starting material instead of INT 2-2. 1 H-NMR (500MHz, DMSO-d6) δ7.42–7.35(m,2H),7.23–7.16(m,2H),5.55(s,2H),4.54(s,2H),4.48(t,J=5.2Hz,1H),3.96–3.89(m ,2H),3.47–3.42(m,2H),3.41(s,3H),1.86–1.80(m,2H),1.73–1.58(m,4H),1.49–1.43(m,1H),1.26–1.15(m,5H).MS(ESI):m / z 469.2[M+H] + .
[0194] Example E22: 8-(3-(Cyclohexyloxy)prop-1-yn-1-yl)-7-(3,4-difluorobenzyl)-1-(3-hydroxypropyl)-3-methyl-3,7-dihydro-1H-purine-2,6-dione
[0195]
[0196] The synthesis method of Example E22 is the same as that of Example E20, except that the intermediate INT 9-1 is used as the starting material instead of INT 2-2. 1 H-NMR (500MHz, DMSO-d6) δ7.48–7.37(m,2H),7.14(d,J=8.0Hz,1H),5.56(s,2H),4.52(s,2H),4.48(t,J=5.2Hz,1H),3.96– 3.89(m,2H),3.43(m,5H),1.84–1.79(m,2H),1.69(m,2H),1.66–1.58(m,2H),1.46(m,1H),1.28–1.14(m,5H).MS(ESI):m / z 487.2[M+H] + .
[0197] Example E23: 7-(4-chlorobenzyl)-8-(3-(cyclohexyloxy)prop-1-yn-1-yl)-1-(3-hydroxypropyl)-3-isopropyl-3,7-dihydro-1H-purine-2,6-dione
[0198]
[0199] The synthesis method of Example E23 is the same as that of Example E20, except that the intermediate INT 16-4 is used as the starting material instead of INT 2-2. 1 H-NMR (500MHz, DMSO-d6) δ7.46–7.41(m,2H),7.34(d,J=8.4Hz,2H),5.56(s,2H),5.04(m,1H),4.52(s,2H),4.48(t,J=5.2Hz,1H),3.94–3.88(m,2 H),3.44(q,J=6.1Hz,2H),1.84–1.79(m,2H),1.72–1.65(m,2H),1.62(m, 2H),1.49(d,J=6.0Hz,6H),1.46(m,1H),1.23–1.12(m,5H); MS(ESI):m / z 513.2[M+H] + .
[0200] Example E24: 7-(4-chlorobenzyl)-8-(3-hydroxybut-1-yn-1-yl)-1-(3-hydroxypropyl)-3-methyl-3,7-dihydro-1H-purine-2,6-dione
[0201]
[0202] INT 2-2 (100 mg, 0.196 mmol), PdCl2(Ph3P)2 (20.6 mg, 0.0294 mmol), CuI (11.17 mg, 0.0588 mmol), 3 mL of triethylamine and 1 mL of DMF were placed in a pressure tube and degassed with nitrogen for 3 min, then 3-butyn-2-ol (28 mg, 0.4 mmol) was added and degassed for another 1 min. The pressure tube was sealed and heated at 60°C for 4 to 6 h. After cooling, it was diluted with ethyl acetate, the insoluble matter was removed by filtration, and the filtrate was evaporated to dryness under reduced pressure to obtain a crude product. Then, it was separated by a flash silica gel column, eluted with MeOH / DCM as the mobile phase, and the target product was collected and evaporated to dryness to obtain 65 mg of a jelly, which was the intermediate INT 24-1.
[0203] The intermediate INT 24-1 (65 mg, 0.13 mmol) was dissolved in 2 mL DCM, and then 0.4 mL TFA was added and stirred at room temperature for 1 h. TLC showed that the reaction was complete. The solvent was evaporated under reduced pressure, and the residue was purified by preparative liquid chromatography column with acetonitrile / water system as mobile phase for elution. The target product was collected and evaporated to dryness to obtain 41 mg of white solid, i.e. Example E24. 1H-NMR (500MHz, DMSO-d6) δ7.47–7.41(m,2H),7.38(d,J=8.6Hz,2H),5.82(d,J=5.6Hz,1H),5.54(s,2H),4.75–4.66(m,1H),4.48 (t,J=5.2Hz,1H),3.96–3.89(m,2H),3.44(q,J=6.1Hz,2H),3.40(s,3H),1.74–1.65(m,2H),1.41(d,J=6.7Hz,3H).MS(ESI):m / z 417.1[M+H] + .
[0204] Example E25: 7-(4-chlorobenzyl)-1-(3-hydroxypropyl)-3-methyl-8-(3-phenoxypropyl-1-yn-1-yl)-3,7-dihydro-1H-purine-2,6-dione
[0205]
[0206] Phenol (2.64 g, 30 mmol) was dissolved in 20 mL of dry DMF, K2CO3 (4.97 g, 36 mmol) was added, and the mixture was stirred for 0.5 h. Then, propargyl bromide (2.63 mL, 30.5 mmol) was added dropwise, and the mixture was allowed to drip for 5 min and reacted at room temperature. TLC showed that the raw material disappeared, saturated brine was added, and the mixture was extracted three times with ethyl acetate. The organic layers were combined, and then washed three times with saturated brine and dried over anhydrous sodium sulfate. The mixture was filtered, and the filtrate was evaporated to dryness under reduced pressure, and then the volume was adjusted to 30 mL with THF to obtain a THF solution of the intermediate INT 25-1 with a concentration of about 1 mol / L.
[0207] INT 2-2 (100 mg, 0.196 mmol), PdCl2(Ph3P)2 (20.6 mg, 0.0294 mmol), CuI (11.2 mg, 0.0588 mmol), 3 mL of triethylamine and 1 mL of DMF were placed in a pressure tube and degassed with nitrogen for 3 min, then the intermediate INT25-1 (1 mL, 1 mmol) was added and degassed for another 1 min. The pressure tube was sealed and heated at 60°C for 4 to 6 h. After cooling, it was diluted with ethyl acetate, the insoluble matter was filtered out, and the filtrate was evaporated to dryness under reduced pressure to obtain a crude product. Then, it was separated by a flash silica gel column, eluted with MeOH / DCM as the mobile phase, and the target product was collected and evaporated to dryness to obtain 87 mg of a white solid, namely the intermediate INT 25-2.
[0208] The intermediate INT 25-2 (87 mg, 0.159 mmol) was dissolved in 2 mL DCM, and then 0.4 mL TFA was added and stirred at room temperature for 1 h. TLC showed that the reaction was complete. The solvent was evaporated under reduced pressure, and the residue was purified by preparative liquid chromatography column with acetonitrile / water system as mobile phase for elution. The target product was collected and evaporated to dryness to obtain 40 mg of white solid, i.e. Example E25. 1 H-NMR(500MHz,DMSO-d6)δ7.38–7.30(m,4H),7.26(d,J=8.4Hz,2H),7.08–7.03(m,2H),7.01(t,J=7.3Hz,1H),5.48(s,2H), 5.23(s,2H),4.48(t,J=5.2Hz,1H),3.94–3.86(m,2H),3.43(q,J=6.2Hz,2H),3.39(s,3H),1.73–1.64(m,2H).MS(ESI):m / z 479.1[M+H] + .
[0209] Example E26: 7-(4-chlorobenzyl)-8-(3-((1-hydroxypropyl-2-oxy)prop-1-yn-1-yl)-1-(3-hydroxypropyl)-3-methyl-3,7-dihydro-1H-purine-2,6-dione
[0210]
[0211] The synthesis method of Example E26 is the same as that of Example E24, except that 2-(2-propyn-1-yloxy)propan-1-ol is used instead of 3-butyn-2-ol as the starting material. 1 H-NMR (500MHz, DMSO-d6) δ7.43(d,J=8.2Hz,2H),7.35(d,J=8.2Hz,2H),5.56(s,2H),4.73(d,J=4.7Hz,1H),4.54(s,2H),4.48(t,J=5.2Hz ,1H),3.97–3.87(m,2H),3.75(p,J=5.7Hz,1H),3.47–3.39(m,5H),3.30(m,2H),1.69(p,J=6.7Hz,2H),1.02(d,J=6.3Hz,3H).MS(ESI):m / z 461.2[M+H] + .
[0212] Example E27: 7-(4-chlorobenzyl)-1-(3-hydroxypropyl)-3-methyl-8-(4-methylpent-1-yn-1-yl)-3,7-dihydro-1H-purine-2,6-dione
[0213]
[0214] The synthesis method of Example E27 is the same as that of Example E24, except that 4-methyl-1-pentyne is used instead of 3-butyne-2-ol as the starting material. 1H-NMR (500 MHz, DMSO-d6) δ 7.47–7.39 (m, 2H), 7.30 (d, J = 8.3 Hz, 2H), 5.54 (s, 2H), 4.47 (t, J = 5.2 Hz, 1H), 3.95–3.88 (m, 2H), 3.47–3.39 (m, 5H), 2.48 (d, J = 6.4 Hz, 2H), 1.88 (hept, J = 6.6 Hz, 1H), 1.69 (p, J = 6.5 Hz, 2H), 0.95 (d, J = 6.7 Hz, 6H). MS (ESI): m / z 429.2 [M+H] + .
[0215] Example E28: 7-(4-chlorobenzyl)-1-(3-hydroxypropyl)-3-methyl-8-(3-((4-oxocyclohexyl)oxy)prop-1-yn-1-yl)-3,7-dihydro-1H-purine-2,6-dione
[0216]
[0217] The synthesis method of Example E28 is the same as that of Example E20, except that 4-hydroxycyclohexanone ethylene glycol acetal is used as the raw material instead of cyclohexanol. 1 H-NMR (500MHz, DMSO-d6) δ7.46–7.41(m,2H),7.36–7.30(m,2H),5.58(s,2H),4.63(s,2H),4.47(t,J=5.2Hz,1H),3.95–3.90(m,2H),3.87(tt,J= 6.6,3.4Hz,1H),3.47–3.39(m,5H),2.35(ddd,J=14.7,8.9,5.9Hz,2H),2 .24–2.15(m,2H),2.05–1.84(m,4H),1.69(p,J=6.6Hz,2H).MS(ESI):m / z 499.2[M+H] + .
[0218] Example E29: 7-(4-chlorobenzyl)-1-(3-hydroxypropyl)-3-methyl-8-(3-(pyrrolidin-1-yl)but-1-yn-1-yl)-3,7-dihydro-1H-purine-2,6-dione
[0219]
[0220] Intermediate INT 24-1 (300 mg, 0.6 mmol) and triethylamine (0.34 mL, 2.4 mmol) were dissolved in 20 mL of ultra-dry dichloromethane, protected with N2, and cooled in an ice bath. Methanesulfonyl chloride (89 mg, 0.78 mmol) was dissolved in 2 mL of dichloromethane, dripped into the reaction flask over 2 min, and stirred for about half an hour. The reaction was completed by TLC detection. The mixture was quenched with saturated aqueous ammonium chloride solution, the dichloromethane phase was separated, washed twice with brine, dried over anhydrous MgSO4, and then separated by a rapid silica gel column to obtain 312 mg of a jelly, namely, intermediate INT 29-1.
[0221] The intermediate INT 29-1 (312 mg, 0.54 mmol) was dissolved in 10 mL of acetonitrile, K2CO3 (149 mg, 1.08 mmol) was added, and then pyrrolidine (58 mg, 0.81 mmol) was added, and the mixture was heated at 75°C for 4 hours under N2 protection. TLC showed that the reaction was complete. The inorganic matter was removed by filtration, and the filtrate was separated by a fast silica gel column to obtain 89 mg of a jelly, namely the intermediate INT 29-2.
[0222] The intermediate INT 29-2 (89 mg, 0.162 mmol) was dissolved in 2 mL DCM, and then 0.4 mL TFA was added and stirred at room temperature for 1 h. TLC showed that the reaction was complete. The solvent was evaporated under reduced pressure, and the residue was purified by preparative liquid chromatography column with acetonitrile / water system as mobile phase for elution. The target product was collected and evaporated to dryness to obtain 42 mg of white solid, i.e. Example E29. 1 H-NMR (500MHz, DMSO-d6) δ7.46–7.41(m,2H),7.28–7.22(m,2H),5.58(s,2H),4.45(t,J=5.2Hz,1H),4.00(d,J=6.8Hz,1H), 3.95–3.88(m,2H),3.43(m,5H),2.48(m,4H),1.69(dq,J=9.0,6.6Hz,2H),1.61(s,4H),1.36(d,J=7.1Hz,3H).MS(ESI):m / z 470.2[M+H] + .
[0223] Example E30: 7-(4-chlorobenzyl)-8-(3-((4-hydroxycyclohexyl)oxy)prop-1-yn-1-yl)-1-(3-hydroxypropyl)-3-methyl-3,7-dihydro-1H-purine-2,6-dione
[0224]
[0225] Example compound E28 (50 mg, 0.1 mmol) was dissolved in 2 mL of methanol, and NaBH4 (7.6 mg, 0.2 mmol) was added and stirred for 5 min. TLC showed that the reaction was complete. The mixture was poured into a saturated NaCl aqueous solution, extracted with ethyl acetate three times, and the organic phases were combined and dried over anhydrous MgSO4. Then, the mixture was separated by a flash silica gel column, and eluted with a dichloromethane / methanol system as the mobile phase. The target product was collected and evaporated to dryness to obtain 38 mg of a white solid, i.e., Example E30. 1 H-NMR (500MHz, DMSO-d6) δ7.46–7.39(m,2H),7.33(dq,J=9.1,2.7Hz,2H),4.51(s,2H),4.47(t,J=5.2Hz,1H),3.95–3.89(m, 2H),3.59–3.37(m,7H),1.90(dt,J=13.2,4.8Hz,1H),1.80–1.64(m,4H),1.55–1.39(m,4H),1.21–1.12(m,1H).MS(ESI):m / z 501.2[M+H] + .
[0226] Example E31: 7-(4-chlorobenzyl)-8-(3,3-dimethylbut-1-yn-1-yl)-1-(3-hydroxypropyl)-3-methyl-3,7-dihydro-1H-purine-2,6-dione
[0227]
[0228] INT 2-2 (100 mg, 0.196 mmol), PdCl2(Ph3P)2 (20.6 mg, 0.0294 mmol), CuI (11.17 mg, 0.0588 mmol), 3 mL of triethylamine and 1 mL of DMF were placed in a pressure tube and degassed with nitrogen for 3 min. Then 3,3-dimethyl-1-butyne (82 mg, 1 mmol) was added and degassed for another 1 min. The pressure tube was sealed and heated at 60 ° C for 6 h. After cooling, it was diluted with ethyl acetate, the insoluble matter was filtered out, and the filtrate was evaporated to dryness under reduced pressure to obtain a crude product. Then, it was separated by a flash silica gel column, eluted with MeOH / DCM as the mobile phase, and the target product was collected and evaporated to dryness to obtain 91 mg of a white solid, which is the intermediate INT 31-1.
[0229] The intermediate INT 31-1 (91 mg, 0.178 mmol) was dissolved in 2 mL DCM, and then 0.4 mL TFA was added and stirred at room temperature for 1 h. TLC showed that the reaction was complete. The solvent was evaporated under reduced pressure, and the residue was purified by preparative liquid chromatography column with acetonitrile / water system as mobile phase for elution. The target product was collected and evaporated to dryness to obtain 52 mg of white solid, i.e. Example E31. 1 H-NMR(500MHz,DMSO-d6)δ7.45(d,J=8.4Hz,2H),7.35(d,J=8.2Hz,2H),5.53(s,2H),4.48(t,J=5.2Hz,1H), 3.93(t,J=7.5Hz,2H),3.44(q,J=6.0Hz,2H),3.40(s,3H),1.70(p,J=6.6Hz,2H),1.30(s,9H); MS(ESI):m / z 429.2[M+H] + .
[0230] Example E32: 7-(4-chlorobenzyl)-8-(cyclopentylethynyl)-1-(3-hydroxypropyl)-3-methyl-3,7-dihydro-1H-purine-2,6-dione
[0231]
[0232] The synthesis method of Example E32 is the same as that of Example E31, except that cyclopentylacetylene is used as the starting material instead of 3,3-dimethyl-1-butyne. 1 HNMR (500MHz, DMSO-d6) δ7.44(d,J=8.0Hz,2H),7.32(d,J=8.5Hz,2H),5.52(s,2H),4.48(t,J=5.2Hz,1H),3.92(t,J =7.5Hz,2H),3.44(q,J=6.1Hz,2H),3.40(s,3H),3.01(p,J=7.4Hz,1H),1.99(m,2H),1.73–1.54(m,8H); MS(ESI):m / z 441.2[M+H] + .
[0233] Example E33: 7-(4-chlorobenzyl)-8-(cyclohexylethynyl)-1-(3-hydroxypropyl)-3-methyl-3,7-dihydro-1H-purine-2,6-dione
[0234]
[0235] The synthesis method of Example E33 is the same as that of Example E31, except that cyclohexylacetylene is used as the starting material instead of 3,3-dimethyl-1-butyne. 1H-NMR (500MHz, DMSO-d6) δ7.44(d,J=8.4Hz,2H),7.32(d,J=8.5Hz,2H),5.53(s,2H),4.48(t,J=5.2Hz,1H),3.92(t,J=7.5Hz ,2H),3.45(m,2H),3.40(s,3H),2.80(m,1H),1.81(m,2H),1.69(m,2H),1.59(m,2H),1.49(m,3H),1.34(m,3H); MS(ESI):m / z 455.2[M+H] + .
[0236] Example E34: 7-(4-chlorobenzyl)-8-(3-cyclohexylpropyl-1-yn-1-yl)-1-(3-hydroxypropyl)-3-methyl-3,7-dihydro-1H-purine-2,6-dione
[0237]
[0238] The synthesis method of Example E34 is the same as that of Example E31, except that 3-cyclohexylpropyne is used instead of 3,3-dimethyl-1-butyne as the starting material. 1 H-NMR (500MHz, DMSO-d6) δ7.45–7.40(m,2H),7.27(d,J=8.2Hz,2H),5.54(s,2H),4.47(t,J=5.2Hz,1H),3.95–3.88(m,2H),3.44(q,J=6 .2Hz,2H),3.41(s,3H),2.46(d,J=6.5Hz,2H),1.73–1.55(m,7H),1.49(m,1H),1.18(m2H),1.06(m,1H),1.00–0.89(m,2H); MS(ESI):m / z 469.2[M+H] + .
[0239] Example E35: 8-((1R, 3S, 5r, 7r)-adamantan-2-yl)ethynyl)-7-(4-chlorobenzyl)-1-(3-hydroxypropyl)-3-methyl-3,7-dihydro-1H-purine-2,6-dione
[0240]
[0241] The synthesis method of Example E35 is the same as that of Example E31, except that 1-ethynyl adamantane is used instead of 3,3-dimethyl-1-butyne as the raw material. 1H-NMR(500MHz,Chloroform-d)δ7.46–7.40(m,2H),7.34(d,J=6.6Hz,1H),4.19(t,J=6.0Hz,2H),3.58(s,3H) ,3.53(m,2H),3.41(m,1H),2.06(m,3H),2.03(m,6H),1.91(p,J=5.7Hz,2H),1.81–1.73(m,6H); MS(ESI):m / z 507.2[M+H] + .
[0242] Example E36: 7-(4-chlorobenzyl)-1-(3-hydroxypropyl)-3-methyl-8-(3-(4-methylpiperidin-1-yl)but-1-yn-1-yl)-3,7-dihydro-1H-purine-2,6-dione
[0243]
[0244] The synthesis method of Example E36 is the same as that of Example E29, except that 4-methylpiperidine is used as the starting material instead of pyrrolidine. 1 H-NMR(500MHz,Chloroform-d)δ7.33(s,4H),5.59(s,2H),4.19(t,J=6.0Hz,2H), 3.83(q,J=7.1Hz,1H),3.60(s,3H),3.53(t,J=5.5Hz,2H),2.93(d,J=10.9Hz,1H), 2.78(d,J=11.0Hz,1H),2.38(d,J=2.8Hz,1H),2.09(d,J=2.6Hz,1H),1.91(p,J=5 .7Hz,2H),1.67(m,6H),1.50(d,J=7.1Hz,3H),0.94(d,J=5.4Hz,3H); MS(ESI):m / z 498.2[M+H] + .
[0245] Example E37: 7-(4-chlorobenzyl)-8-(3-ethoxybut-1-yn-1-yl)-1-(3-hydroxypropyl)-3-methyl-3,7-dihydro-1H-purine-2,6-dione
[0246]
[0247] Potassium hydroxide (364mg, 6.5mmol) was placed in 8mL DMSO, 3-butyn-2-ol (0.37mL, 5mmol) was added, and the mixture was stirred at room temperature for 20min, and then iodoethane (440μL, 5.5mmol) was added, and the mixture was stirred at room temperature overnight. Ice water was added to the flask and neutralized with acetic acid. Then 8mL methyl tert-butyl ether was used for extraction, and the mixture was washed twice with brine and dried over anhydrous magnesium sulfate. Magnesium sulfate was removed by filtration, and the filtrate was fixed to 10mL to obtain a methyl tert-butyl ether solution of 0.5mol / L of the intermediate INT 37-1.
[0248] INT 2-2 (100 mg, 0.196 mmol), PdCl2(Ph3P)2 (20.6 mg, 0.0294 mmol), CuI (11.17 mg, 0.0588 mmol), 3 mL of triethylamine and 1 mL of DMF were placed in a pressure tube and degassed with nitrogen for 3 min. Then, the intermediate INT37-1 (1.6 mL, 0.8 mmol) was added and degassed for another 1 min. The pressure tube was sealed and heated at 60°C for 4 h. After cooling, it was diluted with ethyl acetate, the insoluble matter was filtered out, and the filtrate was evaporated to dryness under reduced pressure to obtain a crude product. Then, it was separated by preparative plate TLC, developed with MeOH / DCM system, and the target product portion was collected to obtain 30 mg of a jelly, namely the intermediate INT 37-2.
[0249] The intermediate INT 37-2 (30 mg, 0.057 mmol) was dissolved in 2 mL DCM, and then 0.4 mL TFA was added and stirred at room temperature for 1 h. TLC showed that the reaction was complete. The solvent was evaporated under reduced pressure, and the residue was purified by preparative liquid chromatography column with acetonitrile / water system as mobile phase for elution. The target product was collected and evaporated to dryness to obtain 12 mg of white solid, i.e. Example E37. 1 H-NMR (500MHz, CD3OD) δ7.38(s,4H),5.65(m,2H),4.52(q,J=6.5Hz,1H),4.11(t,J=7.0Hz,2H),3.73(m,1H),3.62( t,J=6.5Hz,2H),3.54(s,3H),3.51(m,1H),1.87(m,2H),1.53(d,J=7.0Hz,3H),1.21(t,J=7.0Hz,3H); MS(ESI):m / z 445.2[M+H] + .
[0250] Example E38: 7-(4-chlorobenzyl)-8-(3-(cyclopropylmethoxy)but-1-yn-1-yl)-1-(3-hydroxypropyl)-3-methyl-3,7-dihydro-1H-purine-2,6-dione
[0251]
[0252] The synthesis method of Example E38 is the same as that of Example E37, except that bromomethylcyclopropane is used instead of iodoethane as the starting material. 1 H-NMR(500MHz,Chloroform-d)δ7.38(d,J=8.5Hz,2H),7.33(d,J=8.5Hz,2H),5.57(m,2H),4.52(q,J=6.5Hz,1H),4.20(t,J=6.0Hz, 2H),3.59(s,3H),3.54(m,3H),3.33(m,2H),1.91(m,2H),1.61(d,J=7.0Hz,3H),1.06(m,1H),0.59(m,2H),0.23(m,2H); MS(ESI):m / z 471.2[M+H] + .
[0253] Example E39: 7-(4-chlorobenzyl)-1-(3-hydroxypropyl)-3-methyl-8-(3-methyl-3-(4-methylpiperidin-1-yl)but-1-yn-1-yl)-3,7-dihydro-1H-purine-2,6-dione
[0254]
[0255] 3-Chloro-3-methyl-1-butyne (1.02 g, 10 mmol) and 4-methylpiperidine (0.991 g, 10 mmol) were dissolved in 10 mL of ultra-dry tetrahydrofuran, triethylamine (1.67 mL, 12 mmol) was added, and the mixture was protected with N2 and cooled to 0°C in an ice bath. CuI (0.38 g, 2 mmol) was suspended in 5 mL of tetrahydrofuran and added dropwise to the reaction system using a constant pressure dropping funnel, and then reacted at room temperature overnight. The mixture was detected by thin layer chromatography and developed with potassium permanganate as a color developer. After the reaction was completed, a saturated aqueous NaCl solution was poured into the mixture, and the mixture was extracted twice with ethyl acetate, dried over anhydrous MgSO4, filtered and evaporated, and then the volume was adjusted to 10 mL to obtain a tetrahydrofuran solution of the intermediate INT 39-1 with a concentration of 1 mol / L.
[0256] INT 2-2 (100 mg, 0.196 mmol), PdCl2(Ph3P)2 (20.6 mg, 0.0294 mmol), CuI (11.17 mg, 0.0588 mmol), 3 mL of triethylamine and 1 mL of DMF were placed in a pressure tube and degassed with nitrogen for 3 min. Then, the intermediate INT39-1 (1 mL, 1 mmol) was added and degassed for another 1 min. The pressure tube was sealed and heated at 60°C for 4 h. After cooling, it was diluted with ethyl acetate, the insoluble matter was filtered out, and the filtrate was evaporated to dryness under reduced pressure to obtain a crude product. Then, it was separated by a flash silica gel column, eluted with MeOH / DCM as the mobile phase, and the target product was collected and evaporated to dryness to obtain 91 mg of a jelly, namely the intermediate INT 39-2.
[0257] The intermediate INT 39-2 (91 mg, 0.153 mmol) was dissolved in 2 mL DCM, and then 0.4 mL TFA was added and stirred at room temperature for 1 h. TLC showed that the reaction was complete. The solvent was evaporated under reduced pressure, and the residue was purified by preparative liquid chromatography column with acetonitrile / water system as mobile phase for elution. The target product was collected and evaporated to dryness to obtain 46 mg of white solid, namely Example E39. 1 H-NMR(500MHz,Chloroform-d)δ7.33(s,4H),5.59(s,2H),3.61(s,3H),3.53(q,J=5.5Hz,3H),3.10(d,J=10.8Hz,2H),2.16–2. 08(m,2H),2.04(m,1H),1.91(p,J=5.7Hz,2H),1.68(m,4H),1.54(s,6H),1.36–1.32(m,2H),0.94(d,J=5.8Hz,3H).MS(ESI):m / z 512.2[M+H] + .
[0258] Example E40: 7-(4-chlorobenzyl)-8-(cyclopropylethynyl)-1-(3-hydroxypropyl)-3-methyl-3,7-dihydro-1H-purine-2,6-dione
[0259]
[0260] The synthesis method of Example E40 is the same as that of Example E31, except that cyclopropylacetylene is used as the starting material instead of 3,3-dimethyl-1-butyne. 1H-NMR(500MHz,DMSO-d6)δ7.45(m,2H d,J=8.5Hz,2H),7.32(d,J=8.5Hz,2H),5.51(s,2H),4.46(t,J=5.3Hz,1H),3.92(t,J=7.5Hz,2 H),3.44(m,2H),3.39(s,3H),1.74–1.65(m,3H),1.01(m,2H),0.89–0.82(m,2H); MS(ESI):m / z 413.1[M+H] + .
[0261] Example E41: 7-(4-chlorobenzyl)-8-(3-(cyclopentylamino)-3-methylbut-1-yn-1-yl)-1-(3-hydroxypropyl)-3-methyl-3,7-dihydro-1H-purine-2,6-dione
[0262]
[0263] The synthesis method of Example E41 is the same as that of Example E39, except that cyclopentylamine is used as the starting material instead of 4-methylpiperidine. 1 H-NMR (500MHz, DMSO-d6) δ7.46–7.41(m,2H),7.29(d,J=8.4Hz,2H),5.55(s,2H),4.46(t,J=5.2Hz,1H),3.91(dd,J=8.3,6.5Hz,2H),3.43(d ,J=12.8Hz,5H),3.18(d,J=5.2Hz,1H),3.06(p,J=7.2Hz,1H),1.73–1.65(m,4H),1.57–1.48(m,2H),1.36(s,6H),1.21(m,2H); MS(ESI):m / z 498.2[M+H] + .
[0264] Example E42: 7-(4-chlorobenzyl)-8-(3-((3,3-difluorocyclobutyl)amino)-3-methylbut-1-yn-1-yl)-1-(3-hydroxypropyl)-3-methyl-3,7-dihydro-1H-purine-2,6-dione
[0265]
[0266] The synthesis method of Example E42 is the same as that of Example E39, except that 3,3-difluorocyclobutylamine is used instead of 4-methylpiperidine as the starting material. 1H-NMR (500MHz, DMSO-d6) δ7.47–7.41(m,2H),7.31(d,J=8.4Hz,2H),5.55(s,2H),4.47(t,J=5.2Hz,1H),4.12(q,J=5.3Hz,1H),3.96–3.89(m ,2H),3.44(q,J=6.1Hz,2H),3.41(s,3H),3.18(d,J=4.6Hz,2H),2.71(m,2H),2.37(m,2H),1.69(p,J=6.6Hz,2H),1.35(s,6H).MS(ESI):m / z 520.2[M+H] + .
[0267] Example E43: 7-(4-chlorobenzyl)-8-(3-(cyclopropyl(methyl)amino)-3-methylbut-1-yn-1-yl)-1-(3-hydroxypropyl)-3-methyl-3,7-dihydro-1H-purine-2,6-dione
[0268]
[0269] The synthesis method of Example E43 is the same as that of Example E39, except that N-methylcyclopropane is used instead of 4-methylpiperidine as the starting material. 1 H-NMR (500MHz, DMSO-d6) δ7.47–7.40(m,2H),7.30–7.24(m,2H),5.59(s,2H),4.48(t,J=5.2Hz,1H),3.97–3.88(m,2H),3.44(d,J=9.5Hz,5H ),2.25(s,3H),1.74–1.66(m,2H),1.61(tt,J=6.8,3.8Hz,1H),1.43(s,6H),0.52–0.45(m,2H),0.38–0.31(m,2H).MS(ESI):m / z484.2[M+H] + .
[0270] Example E44: 7-(4-chlorobenzyl)-8-(3-(cyclobutylmethoxy)but-1-yn-1-yl)-1-(3-hydroxypropyl)-3-methyl-3,7-dihydro-1H-purine-2,6-dione
[0271]
[0272] The synthesis method of Example E44 is the same as that of Example E37, except that bromomethylcyclobutane is used as the starting material instead of iodoethane. 1H-NMR(500MHz,Chloroform-d)δ7.39(d,J=8.5Hz,2H),7.33(d,J=8.5Hz,2H),5.58( m,2H),4.45(q,J=7.0Hz,1H),4.20(t,J=6.0Hz,2H),3.69(dd,J=7.0,2.0Hz,1H),3.6 0(s,3H),3.55(t,J=6.0Hz,2H),3.45(dd,J=7.0,2.0Hz,1H),3.32(brs,1H,-OH),2.6 0(m,1H),2.08(m,2H),1.92(m,4H),1.74(m,2H),1.59(d,J=6.5Hz,3H); MS(ESI):m / z 485.2[M+H] + .
[0273] Example E45: -(4-chlorobenzyl)-8-(3-(cyclopropylmethoxy)-3-methylbut-1-yn-1-yl)-1-(3-hydroxypropyl)-3-methyl-3,7-dihydro-1H-purine-2,6-dione
[0274]
[0275] The synthesis method of Example E45 is the same as that of Example E37, except that bromomethylcyclopropane is used instead of iodoethane, and 2-methyl-3-butyn-2-ol is used instead of 3-butyn-2-ol as the starting material. 1 H-NMR(500MHz,Chloroform-d)δ7.37(d,J=8.5Hz,2H),7.34(d,J=8.5Hz,2H),5.58(s,2H),4.20(t,J=6.0Hz,2H),3.60(s,3H),3. 54(m,2H),3.41(d,J=7.0Hz,2H),3.31(t,1H,-OH),1.91(m,2H),1.62(s,6H),1.08(m,1H),0.57(m,2H),0.21(m,2H); MS(ESI):m / z 485.2[M+H] + .
[0276] Example E46: 7-(4-chlorobenzyl)-8-(3-(cyclopentyloxy)but-1-yn-1-yl)-1-(3-hydroxypropyl)-3-methyl-3,7-dihydro-1H-purine-2,6-dione
[0277]
[0278] The synthesis method of Example E46 is the same as that of Example E37, except that bromocyclopentane is used instead of iodoethane as the starting material. 1H-NMR(500MHz,Chloroform-d)δ7.41(d,J=8.5Hz,2H),7.33(d,J=8.5Hz,2H),5.58(m,2H),4.48(q,J=6.5Hz,1H),4.20(m,3H),3.60(s,3H) ,3.55(t,J=5.5Hz,2H),2.04(m,1H),1.92(m,2H),1.81(m,1H),1.74(m,4H),1.67(m,1H),1.57(d,J=6.5Hz,3H),1.54(m,1H); MS(ESI):m / z 485.2[M+H] + .
[0279] Example E47: 7-(4-chlorobenzyl)-8-(4-fluorophenyl)ethynyl)-1-(3-hydroxypropyl)-3-methyl-3,7-dihydro-1H-purine-2,6-dione
[0280]
[0281] The synthesis method of Example E47 is the same as that of Example E31, except that 1-ethynyl-4-fluorobenzene is used instead of 3,3-dimethyl-1-butyne as the starting material. 1 H-NMR(500MHz,Chloroform-d)δ7.63(dd,J=8.5,5.5Hz,2H),7.44(d,J=8.5Hz,2H),7.35(d,J=8.5Hz,2H),7.16(t,J=9 .0Hz,2H),5.64(s,2H),4.22(t,J=6.0Hz,2H),3.63(s,3H),3.56(m,2H),3.33(brs,1H,-OH),1.93(m,2H); MS(ESI):m / z 467.1[M+H] + .
[0282] Example E48: 7-(4-chlorobenzyl)-1-(3-hydroxypropyl)-3-methyl-8-(pyridin-2-ylethynyl)-3,7-dihydro-1H-purine-2,6-dione
[0283]
[0284] The synthesis method of Example E48 is the same as that of Example E31, except that 2-ethynylpyridine is used instead of 3,3-dimethyl-1-butyne as the starting material. 1H-NMR(500MHz,Chloroform-d)δ8.74(d,J=6.0Hz,1H),7.81(t,J=7.5Hz,1H),7.68(d,J=7.0Hz,1H),7.55(d,J=8.5Hz,2H),7.42(m,1H ),7.33(d,J=8.5Hz,2H),5.70(s,2H),4.23(t,J=6.0Hz,2H),3.63(s,3H),3.56(m,2H),3.32(brs,1H,-OH),1.94(m,2H); MS(ESI):m / z 450.1[M+H] + .
[0285] Example E49: 7-(4-chlorobenzyl)-1-(3-hydroxypropyl)-3-methyl-8-(thiophen-2-ylethynyl)-3,7-dihydro-1H-purine-2,6-dione
[0286]
[0287] The synthesis method of Example E49 is the same as that of Example E31, except that 2-ethynylthiophene is used instead of 3,3-dimethyl-1-butyne as the starting material. 1 H-NMR(500MHz,Chloroform-d)δ7.52(d,J=5.0Hz,1H),7.50(d,J=3.5Hz,1H),7.45(d,J=8.5Hz,2H),7.35(d,J=8.0Hz,2H),7.1 4(t,J=4.5Hz,1H),5.63(s,2H),4.22(t,J=6.0Hz,2H),3.62(s,3H),3.57(m,2H),3.37(brs,1H,-OH),1.94(m,2H); MS(ESI):m / z 455.1[M+H] + .
[0288] Example E50: 7-(4-chlorobenzyl)-1-(3-hydroxypropyl)-3-methyl-8-(3-oxobut-1-yn-1-yl)-3,7-dihydro-1H-purine-2,6-dione
[0289]
[0290] INT 2-2 (255 mg, 0.5 mmol), PdCl2(Ph3P)2 (52.5 mg, 0.074 mmol), CuI (28.5 mg, 0.15 mmol), 3 mL of triethylamine and 1 mL of DMF were placed in a pressure tube and degassed with nitrogen for 3 min, then 3-butyn-2-ol (175 mg, 2.5 mmol) was added and degassed for another 1 min. The pressure tube was sealed and heated at 60°C for 4 h. After cooling, it was diluted with ethyl acetate, the insoluble matter was removed by filtration, and the filtrate was evaporated to dryness under reduced pressure to obtain a crude product. Then, it was separated by a flash silica gel column, eluted with MeOH / DCM as the mobile phase, and the target product was collected and evaporated to dryness to obtain 91 mg of a jelly, namely the intermediate INT 50-1.
[0291] The intermediate INT 50-1 (100 mg, 0.2 mmol) was dissolved in 2 mL DCM, and then Dess-Martin oxidant (170 mg, 0.4 mmol) was added and stirred at room temperature for 3 h. TLC showed that the reaction was complete. DCM / saturated NaHCO3 aqueous solution was partitioned, and the organic phase was separated. After drying over anhydrous sodium sulfate, it was separated by flash silica gel chromatography, eluted with MeOH / DCM as the mobile phase, and the target product was collected and evaporated to dryness to obtain 73 mg of a jelly, namely the intermediate INT 50-2.
[0292] The intermediate INT 50-2 (73 mg, 0.151 mmol) was dissolved in 2 mL DCM, and then 0.4 mL TFA was added and stirred at room temperature for 1 h. TLC showed that the reaction was complete. The solvent was evaporated under reduced pressure, and the residue was purified by preparative liquid chromatography column with acetonitrile / water system as mobile phase for elution. The target product was collected and evaporated to dryness to obtain 32 mg of white solid, namely Example E50. 1 H-NMR(500MHz,Chloroform-d)δ7.45–7.39(m,2H),7.37–7.31(m,2H),5.62(s,2H),4.22(t,J=6.1Hz, 2H),3.60(s,3H),3.56(t,J=5.6Hz,2H),2.54(s,3H),1.93(p,J=5.8Hz,2H); MS(ESI):m / z415.1[M+H] + .
[0293] Example E51: (E)-7-(4-chlorobenzyl)-8-(2-cyclopropylvinyl)-1-(3-hydroxypropyl)-3-methyl-3,7-dihydro-1H-purine-2,6-dione
[0294]
[0295] INT 2-2 (100 mg, 0.196 mmol), (E)-2-cyclopropylvinylboronic acid pinacol ester (95 mg, 0.49 mmol), Pd(dppf)Cl2 (21.5 mg, 0.029 mmol), Cs2CO3 (191 mg, 0.588 mmol), 1,4-dioxane 10 mL and H2O 3 mL were placed in a pressure tube, degassed with nitrogen for 3 min, the pressure tube was sealed, and heated at 100 ° C for 2 h. After cooling, it was diluted with ethyl acetate, the insoluble matter was filtered out, and the filtrate was evaporated to dryness under reduced pressure to obtain a crude product. Then, it was separated by a flash silica gel column, eluted with MeOH / DCM as the mobile phase, and the target product was collected and evaporated to dryness to obtain 85 mg of a jelly, namely the intermediate INT51-1.
[0296] The intermediate INT 51-1 (85 mg, 0.176 mmol) was dissolved in 2 mL DCM, and then 0.4 mL TFA was added and stirred at room temperature for 1 h. TLC showed that the reaction was complete. The solvent was evaporated under reduced pressure, and the residue was purified by preparative liquid chromatography column with acetonitrile / water system as mobile phase for elution. The target product was collected and evaporated to dryness to obtain 40 mg of white solid, namely Example E51. 1 H-NMR (500MHz, Chloroform-d) δ7.38–7.32(m,2H),7.22–7.13(m,2H),6.56(dd,J=15.1,10.0Hz,1H),6.37(d,J=15.1Hz,1H),5.56(s,2H),4.23–4. 13(m,2H),3.61(s,3H),3.56–3.49(m,2H),1.91(p,J=5.8Hz,2H),1.68–1. 62(m,1H),1.07–0.95(m,2H),0.76–0.71(m,2H); MS(ESI):m / z413.1[M+H] + .
[0297] Example E52: 7-(4-chlorophenyl)-1-(3-hydroxypropyl)-3-methyl-8-(3-methyl-3-(methylsulfonyl)but-1-yn-1-yl)-3,7-dihydro-1h-purine-2,6-dione
[0298]
[0299] Sodium methanesulfonate (830 mg, 7.033 mmol) and CuCl (77 mg, 0.778 mmol) were dissolved in 10 mL DMF, 3-chloro-3-methyl-1-butyne (1 g, 9.8 mmol) was slowly added dropwise, and heated at 40 ° C for 12 h. TLC showed that the reaction was complete. After filtration, the filtrate was concentrated and separated by a flash silica gel column, eluted with MeOH / DCM as the mobile phase, and the target product was collected and evaporated to dryness to obtain 184 mg of a jelly, namely the intermediate INT 52-1.
[0300] INT 2-2 (100 mg, 0.196 mmol), PdCl2(Ph3P)2 (20.6 mg, 0.0294 mmol), CuI (11.17 mg, 0.0588 mmol), 3 mL of triethylamine and 1 mL of DMF were placed in a pressure tube and degassed with nitrogen for 3 min. Then, the intermediate INT52-1 (85 mg, 0.582 mmol) was added and degassed for another 1 min. The pressure tube was sealed and heated at 60 ° C for 4 h. After cooling, it was diluted with ethyl acetate, the insoluble matter was filtered out, and the filtrate was evaporated to dryness under reduced pressure to obtain a crude product. Then, it was separated by a flash silica gel column, eluted with MeOH / DCM as the mobile phase, and the target product was collected and evaporated to dryness to obtain 50 mg of a jelly, namely the intermediate INT 52-2.
[0301] The intermediate INT 52-2 (50 mg, 0.089 mmol) was dissolved in 2 mL DCM, and then 0.4 mL TFA was added and stirred at room temperature for 1 h. TLC showed that the reaction was complete. The solvent was evaporated under reduced pressure, and the residue was purified by preparative liquid chromatography column with acetonitrile / water system as mobile phase for elution. The target product was collected and evaporated to dryness to obtain 25 mg of white solid, namely Example E52. 1 H-NMR(500MHz,Chloroform-d)δ7.44–7.37(m,2H),7.37–7.32(m,2H),5.60(s,2H),4.22(t,J=6 .1Hz,2H),3.60(s,3H),3.58–3.53(m,2H),3.00(s,3H),1.93(m,2H),1.82(s,6H); MS(ESI):m / z 493.1[M+H] + .
[0302] Example E53: (E)-7-(4-chlorobenzyl)-1-(3-hydroxypropyl)-3-methyl-8-(pent-1-en-1-yl)-3,7-dihydro-1H-purine-2,6-dione
[0303]
[0304] INT 2-2 (100 mg, 0.196 mmol), trans-1-penten-1-ylboronic acid pinacol ester (96.1 mg, 0.49 mmol), Pd(dppf)Cl2 (21.5 mg, 0.029 mmol), Cs2CO3 (191 mg, 0.588 mmol), 1,4-dioxane 10 mL and H2O 3 mL were placed in a pressure tube, degassed with nitrogen for 3 min, the pressure tube was sealed, and heated at 100 ° C for 2 h. After cooling, it was diluted with ethyl acetate, the insoluble matter was filtered out, and the filtrate was evaporated to dryness under reduced pressure to obtain a crude product. Then, it was separated by a flash silica gel column, eluted with MeOH / DCM as the mobile phase, and the target product was collected and evaporated to dryness to obtain 100 mg of a jelly, namely the intermediate INT51-1.
[0305] The intermediate INT 51-1 (100 mg, 0.2 mmol) was dissolved in 2 mL DCM, and then 0.4 mL TFA was added and stirred at room temperature for 1 h. TLC showed that the reaction was complete. The solvent was evaporated under reduced pressure, and the residue was purified by preparative liquid chromatography column with acetonitrile / water system as mobile phase for elution. The target product was collected and evaporated to dryness to obtain 50 mg of white solid, namely Example E51. 1 H-NMR (500MHz, Chloroform-d) δ7.37–7.31(m,2H),7.20–7.14(m,2H),7.10(dt,J=15.4,7.1Hz,1H),6.31(dt,J=15.4,1.6Hz,1H),5.57(s,2H),4.26–4. 09(m,2H),3.63(s,3H),3.57–3.49(m,2H),2.30(qd,J=7.2,1.6Hz,2H),1.91 (p, J=5.8Hz, 2H), 1.56 (p, J=7.4Hz, 2H), 0.98 (t, J=7.3Hz, 3H); MS (ESI): m / z 417.2[M+H] + .
[0306] Example E54: Ethyl propionate 3-(7-(4-chlorobenzyl)-1-(3-hydroxypropyl)-3-methyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)
[0307]
[0308] Dissolve trimethylsilylene (980 mg, 10 mmol) in 20 mL of ether, add isopropylmagnesium bromide (1.617 g, 11 mmol), stir at room temperature for 1 hour, heat under reflux at 150 ° C for 15 min, cool to room temperature, add tetraethyl orthocarbonate (2.208 g, 11.5 mmol), and stir at 45 ° C for 12 h. TLC shows that the reaction is complete. Distribute with EA / saturated NaCl aqueous solution, separate the organic phase, dry with anhydrous sodium sulfate, and separate with a fast silica gel column, elute with PE / EA as the mobile phase, collect the target product, and evaporate to dryness to obtain 1.05 g of liquid, i.e., intermediate INT 54-1.
[0309] INT 54-1 (1 g, 4.098 mmol) was dissolved in 5 mL THF, TBAF (5.3 mL, 6.147 mmol) was added, and the mixture was stirred at room temperature for 15 min. TLC showed that the reaction was complete, and the solvent was removed by distillation under reduced pressure. The product was separated by flash silica gel chromatography, and PE / EA was used as the mobile phase for elution. The target product was collected and evaporated to dryness to obtain 700 mg of liquid, which was the intermediate INT 54-2.
[0310] INT 2-2 (100 mg, 0.196 mmol), PdCl2(Ph3P)2 (20.6 mg, 0.0294 mmol), CuI (11.17 mg, 0.0588 mmol), 3 mL of triethylamine and 1 mL of DMF were placed in a pressure tube and degassed with nitrogen for 3 min. Then, the intermediate INT54-2 (100 mg, 0.582 mmol) was added and degassed for another 1 min. The pressure tube was sealed and heated at 60 ° C for 4 h. After cooling, it was diluted with ethyl acetate, the insoluble matter was filtered out, and the filtrate was evaporated to dryness under reduced pressure to obtain a crude product. Then, it was separated by a flash silica gel column, eluted with MeOH / DCM as the mobile phase, and the target product was collected and evaporated to dryness to obtain 80 mg of a jelly, namely the intermediate INT 54-3.
[0311] The intermediate INT 52-2 (80 mg, 0.133 mmol) was dissolved in 2 mL DCM, and then 0.4 mL TFA was added and stirred at room temperature for 1 h. TLC showed that the reaction was complete. The solvent was evaporated under reduced pressure, and the residue was purified by preparative liquid chromatography column with acetonitrile / water system as mobile phase for elution. The target product was collected and evaporated to dryness to obtain 45 mg of white solid, namely Example E54. 1H-NMR(500MHz,Chloroform-d)δ7.48–7.43(m,2H),7.38–7.32(m,2H),5.63(s,2H),4.40(q,J=7.1Hz,2H),4.2 2(t,J=6.1Hz,2H),3.60(s,3H),3.58–3.54(m,2H),1.93(p,J=5.8Hz,2H),1.42(t,J=7.1Hz,3H); MS(ESI):m / z 445.1[M+H] + .
[0312] Example E55: 5-(4-chlorobenzyl)-6-(cyclopentylethynyl)-3-(3-hydroxypropyl)-1-methyl-1,5-dihydro-2H-pyrrolo[3,2-d]pyrimidine-2,4(3H)-dione
[0313]
[0314] 6-Chlorouracil (10 g, 68.493 mmol) was dissolved in 40 mL DMSO, and K2CO3 (4.8 g, 34.783 mmol) and CH3I (12.7 mL, 205.48 mmol) were added in sequence, and stirred at room temperature for 3 h. TLC showed that the reaction was complete, 50 mL H2O was added, and the mixture was filtered and washed with water to obtain 7.9 g of a white solid, which was the intermediate INT 55-1.
[0315] The intermediate INT 55-1 (1 g, 6.25 mmol) was dissolved in 10 mL DMF, K2CO3 (1.73 g, 12.5 mmol) and 3-bromopropyl methyl ether (1.07 mL, 9.375 mmol) were added, and heated at 60°C for 3 h. TLC showed that the reaction was complete, and the organic phase was separated by EA / saturated NaCl aqueous solution partitioning, and the organic phase was separated, dried over anhydrous sodium sulfate, and separated by a flash silica gel column, eluted with DCM / MeOH as the mobile phase, and the target product was collected and evaporated to dryness to obtain 800 mg of a jelly, namely the intermediate INT 55-2.
[0316] The intermediate INT 55-2 (1 g, 4.31 mmol) was dissolved in 3 mL of concentrated sulfuric acid, stirred at 0°C for 5 min, and 3 mL of concentrated nitric acid was slowly added dropwise, and stirred at 0°C for 1 h. TLC showed that the reaction was complete, EA / ice water was partitioned, the organic layer was washed four times with saturated brine, dried over anhydrous sodium sulfate, and separated by a flash silica gel column, eluted with DCM / MeOH as the mobile phase, and the target product was collected and evaporated to dryness to obtain 800 mg of a jelly, namely the intermediate INT55-3.
[0317] Diethyl malonate (3.24 mL, 21.66 mmol) was dissolved in 10 mL of dry 1,4-dioxane, potassium tert-butoxide (2.16 g, 19.494 mmol) was added, and the mixture was stirred at room temperature for 10 min, and then intermediate INT 55-3 (3 g, 10.83 mmol) was added, and the mixture was stirred at room temperature for 1 h. TLC showed that the reaction was complete, 2M HCl was adjusted to acidic, EA / saturated NaCl aqueous solution was used for partitioning, and the organic phase was separated, dried over anhydrous sodium sulfate, and separated by a flash silica gel column, eluted with DCM / MeOH as the mobile phase, and the target product was collected and evaporated to dryness to obtain 3.2 g of a jelly, namely intermediate INT 55-4.
[0318] The intermediate INT 55-4 (3 g, 7.463 mmol) was dissolved in 15 mL of acetic acid, heated to 60 ° C, and zinc powder (7.3 g, 111.94 mmol) was added, and the reaction was carried out in a pressure tube at 120 ° C for 12 hours. TLC showed that the reaction was complete, and the crude product was evaporated under reduced pressure. Then, it was separated by a flash silica gel column, eluted with MeOH / DCM as the mobile phase, and the target product was collected and evaporated to dryness to obtain 1.8 g of a jelly, namely the intermediate INT 55-5.
[0319] The intermediate INT 55-5 (100 mg, 7.463 mmol) was dissolved in 3 mL of dry 1,4-dioxane, and phosphorus oxybromide (340 mg, 22.389 mmol) was added under nitrogen protection, and stirred at 100°C for 1 h. TLC showed that the reaction was complete, and the organic phase was separated by EA / saturated NaHCO3 aqueous solution, dried over anhydrous sodium sulfate, and separated by flash silica gel chromatography, eluted with DCM / MeOH as the mobile phase, and the target product was collected and evaporated to dryness to obtain 90 mg of a jelly, namely the intermediate INT 55-6.
[0320] The intermediate INT 55-6 (90 mg, 0.286 mmol) was dissolved in 5 mL DMF, K2CO3 (1.73 g, 12.5 mmol) and 4-chlorobenzyl bromide (116 mg, 0.572 mmol) were added, and heated at 60°C for 2 h. TLC showed that the reaction was complete, and the organic phase was separated by EA / saturated NaCl aqueous solution, dried over anhydrous sodium sulfate, and separated by flash silica gel chromatography, eluted with DCM / MeOH as the mobile phase, and the target product was collected and evaporated to dryness to obtain 80 mg of a white solid, namely the intermediate INT 55-7.
[0321] The intermediate INT 55-7 (40 mg, 0.091 mmol) was dissolved in 3 mL of dry DCM, and 182 μL of 1 M BBr3 solution was added at 0°C, and stirred at this temperature for 1 h. TLC showed that the reaction was complete, and the crude product was evaporated under reduced pressure. Then, it was separated by a flash silica gel column, eluted with MeOH / DCM as the mobile phase, and the target product was collected and evaporated to obtain 30 mg of a white solid, namely the intermediate INT 55-8.
[0322] INT 55-8 (50 mg, 0.118 mmol), PdCl2(Ph3P)2 (12 mg, 0.0177 mmol), CuI (7 mg, 0.0354 mmol), 3 mL of triethylamine and 1 mL of DMF were placed in a pressure tube and degassed with nitrogen for 3 min. Then, cyclopentylacetylene (56 mg, 0.588 mmol) was added and degassed for another 1 min. The pressure tube was sealed and heated at 60°C for 4 h. After cooling, it was diluted with ethyl acetate, the insoluble matter was filtered out, and the filtrate was evaporated to dryness under reduced pressure to obtain a crude product. Then, it was separated by a rapid silica gel chromatography column, eluted with MeOH / DCM as the mobile phase, and the target product portion was collected and evaporated to dryness to obtain 40 mg of a colloid. The crude product was purified by a preparative liquid chromatography column, eluted with an acetonitrile / water system as the mobile phase, and the target product portion was collected and evaporated to dryness to obtain 25 mg of a white solid, namely Example E55. 1 H-NMR(500MHz,Chloroform-d)δ7.30(s,4H),6.11(s,1H),5.61(s,2H),4.26–4.07(m,2H),3.51(t,J=5.5Hz,2H), 3.45(s,3H),2.91(p,J=7.4Hz,1H),2.05(d,J=10.7Hz,3H),1.90(p,J=5.7Hz,2H),1.84–1.54(m,3H); MS(ESI):m / z 440.2[M+H] + .
[0323] Example E56: (E)-5-(4-chlorobenzyl)-6-(4-chlorophenylvinyl)-3-(3-hydroxypropyl)-1-methyl-1,5-dihydro-2H-pyrrolo[3,2-d]pyrimidine-2,4(3H)-dione
[0324]
[0325] INT 55-8 (25 mg, 0.049 mmol), (E)-(4-chlorophenylvinyl)boronic acid (22.3 mg, 0.122 mmol), Pd(dppf)Cl2 (5.38 mg, 0.007 mmol), Cs2CO3 (48 mg, 0.147 mmol), 1,4-dioxane 10 mL and H2O 3 mL were placed in a pressure tube, degassed with nitrogen for 3 min, the pressure tube was sealed, and heated at 100°C for 2 h. After cooling, it was diluted with ethyl acetate, the insoluble matter was filtered out, and the filtrate was evaporated to dryness under reduced pressure to obtain a crude product. Then, it was separated by a flash silica gel column, eluted with MeOH / DCM as the mobile phase, and the target product was collected and evaporated to dryness to obtain 25 mg of a colloid. The crude product was purified by a preparative liquid chromatography column, eluted with an acetonitrile / water system as the mobile phase, and the target product was collected and evaporated to dryness to obtain 15 mg of a white solid, namely Example E56. 1 H-NMR(500MHz,Chloroform-d)δ7.37(s,4H),7.34–7.30(m,2H),7.16–7.03(m,3H),6.91(d,J=16.1Hz,1H), 6.31(s,1H),5.78(s,2H),4.22(t,J=5.9Hz,2H),3.55(s,3H),3.53(s,2H),1.96–1.87(m,2H); MS(ESI):m / z 484.1[M+H] + .
[0326] Example E57: (E)-5-(4-chlorobenzyl)-6-(2-cyclopentylprop-1-en-1-yl)-3-(3-hydroxypropyl)-1-methyl-1,5-dihydro-2H-pyrrolo[3,2-d]pyrimidine-2,4(3H)-dione
[0327]
[0328] Boric acid pinacol ester (1.05g, 4.134mmol), potassium tert-butoxide (536mg, 4.785mmol), IMesCuCl (5mg, 0.012mmol) were dissolved in THF in sequence, cooled to 0℃ and stirred for 10min under nitrogen protection. Cyclopentylacetylene (300mg, 3.191mmol) and CH3I (1.359g, 9.574mmol) were added and stirred at room temperature for 12h. TLC showed that the reaction was complete, and the organic phase was separated by EA / saturated NH4Cl aqueous solution, dried over anhydrous sodium sulfate, and separated by flash silica gel chromatography, eluted with PE / EA as the mobile phase, and the target product was collected and evaporated to dryness to obtain 350mg of colloid, i.e., intermediate INT 57-1.
[0329] INT 55-8 (25 mg, 0.049 mmol), INT 57-1 (34.7 mg, 0.147 mmol), Pd(dppf)Cl2 (5.38 mg, 0.007 mmol), Cs2CO3 (48 mg, 0.147 mmol), 1,4-dioxane 10 mL and H2O 3 mL were placed in a pressure tube, degassed with nitrogen for 3 min, the pressure tube was sealed, and heated at 100°C for 2 h. After cooling, it was diluted with ethyl acetate, the insoluble matter was filtered out, and the filtrate was evaporated to dryness under reduced pressure to obtain a crude product. Then, it was separated by a flash silica gel column, eluted with MeOH / DCM as the mobile phase, and the target product was collected and evaporated to dryness to obtain 25 mg of a colloid. The crude product was purified by a preparative liquid chromatography column, eluted with an acetonitrile / water system as the mobile phase, and the target product was collected and evaporated to dryness to obtain 18 mg of a white solid, namely Example E57. 1 H-NMR(500MHz,Chloroform-d)δ7.29–7.25(m,2H),7.13–6.99(m,2H),6.05(d,J= 1.6Hz,1H),5.94(s,1H),5.59(s,2H),4.20(q,J=6.1Hz,2H),3.53(d,J=5.3Hz,2H ),3.51(s,3H),2.65–2.50(m,1H),1.92(d,J=5.8Hz,2H),1.89(d,J=1.3Hz,3H),1 .87–1.78(m,2H),1.77–1.68(m,2H),1.67(s,2H),1.50–1.36(m,2H); MS(ESI):m / z 456.2[M+H] + .
[0330] Example E58: (E)-7-(4-chlorobenzyl)-8-(2-cyclopentylprop-1-en-1-yl)-1-(3-hydroxypropyl)-3-methyl-3,7-dihydro-1H-purine-2,6-dione
[0331]
[0332] INT 2-2 (100 mg, 0.196 mmol), INT 57-1 (115.6 mg, 0.49 mmol), Pd(dppf)Cl2 (21.5 mg, 0.029 mmol), Cs2CO3 (191 mg, 0.588 mmol), 1,4-dioxane 10 mL and H2O 3 mL were placed in a pressure tube, degassed with nitrogen for 3 min, the pressure tube was sealed, and heated at 100 ° C for 2 h. After cooling, it was diluted with ethyl acetate, the insoluble matter was filtered out, and the filtrate was evaporated to dryness under reduced pressure to obtain a crude product. Then, it was separated by a flash silica gel column, eluted with MeOH / DCM as the mobile phase, and the target product was collected and evaporated to dryness to obtain 80 mg of a jelly, which is the intermediate INT 58-2.
[0333] The intermediate INT 58-2 (80 mg, 0.191 mmol) was dissolved in 2 mL DCM, and then 0.4 mL TFA was added and stirred at room temperature for 1 h. TLC showed that the reaction was complete. The solvent was evaporated under reduced pressure, and the residue was purified by preparative liquid chromatography column with acetonitrile / water system as mobile phase for elution. The target product was collected and evaporated to dryness to obtain 50 mg of white solid, i.e. Example E58. 1 H-NMR(500MHz,Chloroform-d)δ7.31(d,J=8.2Hz,2H),7.17(d,J=8.3Hz,2H),6.10(s,1H),5.52(s,2H),4.20(h,J=7.1,6.6Hz,2H),3.63(s,3H),3 .56(t,J=5.5Hz,2H),2.63(ddd,J=17.0,9.6,7.4Hz,1H),2.30–2.12(m,3 H),1.99–1.79(m,4H),1.78–1.56(m,4H),1.54–1.40(m,2H); MS(ESI):m / z 457.2[M+H] + .
[0334] Example E59: (E)-5-(4-chlorobenzyl)-6-(3,3-dimethylbut-1-en-1-yl)-3-(3-hydroxypropyl)-1-methyl-1,5-dihydro-2H-pyrrolo[3,2-d]pyrimidine-2,4(3H)-dione
[0335]
[0336] The synthesis method of Example E59 is the same as that of Example E56, except that trans-(3,3-dimethylbuten-1-yl)boronic acid pinacol ester is used instead of (E)-(4-chlorophenylvinyl)boronic acid as the starting material. 1H NMR(500MHz,Chloroform-d)δ7.30(d,J=8.0Hz,2H),7.12–7.06(m,2H),6.37(d,J=16.0Hz,1H),6.19(d,J=16.0Hz,1H),6.10(s,1 H),5.67(s,2H),4.26–4.12(m,2H),3.53(d,J=5.4Hz,2H),3.51(d,J=2.2Hz,3H),1.91(p,J=5.8Hz,2H),1.10(s,9H); MS(ESI):m / z 430.2[M+H] + .
[0337] Example E60: 5-(4-chlorobenzyl)-6-(3,3-dimethylbut-1-yn-1-yl)-3-(3-hydroxypropyl)-1-methyl-1,5-dihydro-2H-pyrrolo[3,2-d]pyrimidine-2,4(3H)-dione
[0338]
[0339] INT 55-8 (40 mg, 0.094 mmol), PdCl2(Ph3P)2 (9.9 mg, 0.014 mmol), CuI (5.36 mg, 0.028 mmol), 3 mL of triethylamine and 1 mL of DMF were placed in a pressure tube, degassed with nitrogen for 3 min, and then 3,3-dimethyl-1-butyne (38.8 mg, 0.471 mmol) was added, and then degassed for another 1 min. The pressure tube was sealed and heated at 60°C for 4 h. After cooling, it was diluted with ethyl acetate, the insoluble matter was removed by filtration, and the filtrate was evaporated to dryness under reduced pressure to obtain a crude product. Then, it was separated by a flash silica gel column, eluted with MeOH / DCM as the mobile phase, and the target product portion was collected and evaporated to dryness to obtain 35 mg of a colloid. The crude product was purified by a preparative liquid chromatography column, eluted with an acetonitrile / water system as the mobile phase, and the target product portion was collected and evaporated to dryness to obtain 20 mg of a white solid, namely Example E60. 1 H-NMR(500MHz,Chloroform-d)δ7.30(t,J=2.3Hz,4H),6.12(s,1H),5.61(s,2H),4.19(q,J=6. 1Hz, 2H), 3.52 (t, J=5.5Hz, 2H), 3.45 (s, 3H), 1.90 (p, J=5.6Hz, 2H), 1.35 (s, 9H); MS (ESI): m / z 428.2[M+H] + .
[0340] Example E61: 5-(4-chlorobenzyl)-3-(3-hydroxypropyl)-1-methyl-6-(phenylethynyl)-1,5-dihydro-2H-pyrrolo[3,2-d]pyrimidine-2,4(3H)-dione
[0341]
[0342] The synthesis method of Example E61 is the same as that of Example E60, except that phenylacetylene is used as the starting material instead of 3,3-dimethyl-1-butyne. 1 H-NMR(500MHz,Chloroform-d)δ7.56–7.51(m,2H),7.47–7.40(m,3H),7.39–7.30(m,4H),6.29(s,1H) ,5.72(s,2H),4.30–4.14(m,2H),3.57–3.52(m,2H),3.50(s,3H),1.92(p,J=5.6Hz,2H);MS(ESI):m / z 448.1[M+H] + .
[0343] 2. Pharmacological Examples
[0344] 1. Determination of TRPC4 and TRPC5 Inhibitory Activity
[0345] HEK-293 cells expressing hTRPC4 or hTRPC5 were seeded into PDL-coated black-bottomed 96-well plates at 2 × 10 cells per well. 4 After 8 hours of culture, the original culture medium was discarded, and 60 μL of Fluo-4 / AM dye with a final concentration of 4 μM was added, and incubated at 37°C for 60 minutes. Then, the cell plate was rinsed 5 times with calcium flow detection buffer and placed in a 30°C preheated (Molecular Devices, Sunnyvale, CA, USA), excited at a wavelength of 488nm, and continuously recorded fluorescence signals in the range of 515-535nm at a sampling frequency of 1s. After recording for 60 seconds, solvent control, test compound and positive inhibitor HC608 (final concentration of 100nM) were added, and the signal was collected for 300s. Then, the agonist Englerin A (EA) (final concentration of 0.3nM) was added, and the fluorescence signal was collected for 600 seconds. The fluorescence signal in the trajectory diagram is expressed as F / F0, where F is the fluorescence signal at different time points and F0 is the basic fluorescence signal, that is, the average of the fluorescence signals at the first 10 time points. The dose-effect diagram first takes F / F0=1 as the baseline, calculates the area under the curve of the change in fluorescence intensity after the addition of EA, and combines the area under the curve with the log value of the compound concentration to calculate the IC using log[Inhibitor] vs.response—Variable slope. 50 value.
[0346] 2. Determination of liver microsome stability
[0347] First, prepare 0.1M pH 7.4 Tris buffer, then use this buffer to prepare a 100mM MgCl2 solution and a 10mM coenzyme factor NADPH solution. The test compound is first prepared into a mother solution with DMSO, and then diluted with water and 0.1% BSA to the working concentration when used. During the assay, the TRIS buffer of liver microsomes (final concentration of 0.33mg / mL microsomal protein), MgCl2 solution (final concentration of 5mM), test compound solution (final concentration of 1μM) and NADPH solution (final concentration of 1mM) are incubated at 37°C, and methanol is added at 0, 7, 17, 30 and 60 minutes to terminate the reaction. The residual concentration of the test compound is determined by LC / MS / MS method. Calculation of half-life: T 1 / 2 =0.693 / k e . k e It is the slope (absolute value) of the linear regression line when plotting semi-logarithmically. Take the semi-logarithm of the remaining percentage of substrate and plot the semi-logarithmic graph against the reaction time.
[0348] 3. Activity and microsome stability evaluation results
[0349] TRPC4 / 5 inhibitory activity and liver microsomal stability are shown in the following table:
[0350]
[0351]
[0352]
[0353] Note: –, not tested.
[0354] In the above table, compound C31 is compound 31 on pages 169 and 256 of patent application WO2014143799, and C297 is compound 297 on pages 210 and 301, both of which are potent TRPC5 inhibitors. C31 is also referred to as HC-608 and Pico145 in the literature (PLoS ONE.2018, 13, e0191225.). As can be seen from the measurement results, compared with C31 and C297, many compounds shown in the general formula (I) of the present invention, including compound E37 with a structure close to C297, unexpectedly showed stronger TRPC4 and TRPC5 inhibitory activity and faster liver microparticle metabolism rate. Patent application WO2014143799 discloses the use of compound C31 in treating neuropsychiatric diseases such as depression and anxiety, and patent application US20220031706 discloses the use of compound C31 in treating metabolic diseases such as diabetes and obesity. The present invention discloses the use of the compound represented by the general formula (I) represented by compound E37 for treating skin diseases such as psoriasis. When used as a topical skin drug, the compound is absorbed into the blood circulation after being absorbed through the skin to exert its medicinal effect. If the compound is metabolized and cleared by the liver more quickly, it indicates that systemic side effects can be more effectively avoided and have better safety.
[0355] 4. Evaluation of the toxicity of compounds to liver and kidney cells
[0356] 4.1 Isolation of primary mouse hepatocytes and toxicity evaluation
[0357] Two-month-old male C57 / BL-6 mice were anesthetized with tribromoethanol and fixed on a workbench with the abdomen facing upward. 2+ The liver was perfused with HBSS buffer (containing 5.5 mM glucose and 20 mM HEPES, pH = 7.4) at a rate of 4-5 mL / min, and then with 5 mM Ca 2+ The liver was perfused with a solution of 0.05% collagenase IV for 10 minutes. The resulting cell suspension was filtered through two nylon meshes with a mesh size of 70 μm, and then centrifuged at 50×g for 2 minutes at 4°C to collect cell clumps. The cell clumps were resuspended in 50 mL of the solution, 12.5 mL of the suspension was taken, 10.8 mL of Percoll solution and 1.2 mL of 10-fold concentrated DMEM solution (containing 4.5 g / l glucose) were added. The mixture was centrifuged at 500 g for 5 minutes, and the cell clumps were washed twice with DMEM solution. By morphological analysis, 95% of the isolated cells were judged to be hepatocytes. The cell viability was between 85% and 95% as determined by the trypan blue exclusion method.
[0358] The isolated mouse primary hepatocytes were seeded in 96-well culture plates (1.5×104 Cells / well) were cultured in low-glucose DMEM containing 10% fetal bovine serum and 100 units / ml of penicillin and streptomycin. After 4 hours of culture, serum-free DMEM was used. The compound to be tested was pre-dissolved in DMSO to prepare a 100mM stock solution, and then diluted to the specified concentration with serum-free DMEM. 100μL was added to the well to make the final concentration of the compound 1 or 10μM, and the culture was continued for 24 hours. The culture medium was then removed, and the cells were cultured with 0.5mg / mL MTT (in culture medium) at 37°C for another 2 hours. After removing the supernatant, 150μL of dimethyl sulfoxide was added to each well, and the absorbance was measured at 570nm.
[0359] 4.2 HK-2 kidney cell culture and toxicity evaluation
[0360] After HK-2 kidney cells purchased from commercial sources were revived, they were cultured in 96-well plates using DMEM / F12 complete medium containing penicillin / streptomycin, HEPES (4-hydroxyethylpiperazineethanesulfonic acid) and 10% fetal bovine serum, with approximately 2.5 × 10 cells seeded per well. 3 cells. After culturing for about 24 hours, the culture medium was removed and 100 μL of the pre-prepared culture medium dilution of the test compound was added to make the final concentration of the compound 1 or 10 μM, and the culture was continued for 24 hours. The culture medium was then removed and the cells were cultured with 0.5 mg / mL MTT (in culture medium) at 37°C for another 2 hours. After removing the supernatant, 150 μL of dimethyl sulfoxide was added to each well and the absorbance was measured at 570 nm.
[0361] 4.3 Toxicity test results
[0362] The results of the liver and kidney cell toxicity assay of the compounds are shown in the following table:
[0363]
[0364] Note: –, cell viability is not reduced; +, cell viability is reduced by 10-30%; ++, cell viability is reduced by 30-60%; +++, cell viability is reduced by 60-90%.
[0365] It can be seen from the measurement results that compared with compounds C31 and C297 disclosed in patent application WO2014143799, the compound represented by general formula (I) of the present invention has less effect on the viability of liver and kidney cells and exhibits lower cytotoxicity.
[0366] 5. Effects of compounds on keratinocyte proliferation
[0367] 5.1 Culture of human immortalized keratinocyte cell line HaCaT
[0368] HaCaT cells were cultured in DMEM medium containing 10% FBS, 10mM HEPES and 100U / mL penicillin / streptomycin at 37°C, 5% CO2 and 95% humidity. When the cells grew to 70-80% confluence, discard the old medium, rinse with PBS twice, then add trypsin-EDTA, digest at 37°C for 5-7 minutes, and when the cells became round and the intercellular space became larger, add DMEM containing FBS to terminate the digestion, and pipette the cells to collect the cell suspension, centrifuge at 800rpm for 5 minutes, discard the supernatant, resuspend the cells with DMEM containing 10% FBS, take a part of the cell suspension and transfer it to a new cell bottle for further culture. Or adjust the cell concentration with DMEM containing 2% FBS, and then spread it on a cell plate for the next experiment.
[0369] 5.2 BrdU incorporation assay
[0370] A final concentration of 10 μM BrdU (5-bromodeoxyuridine) was added to the cell culture environment. After continued culture at 37°C for 3 hours, the solution in the wells was discarded and the cells were rinsed 3 times with PBS; the cells were fixed with 4% paraformaldehyde for 30 minutes and rinsed 3 times with PBS; the cells were treated with 0.1% TritonX-100 for 15 minutes and rinsed 3 times with PBS; then treated with 2M HCl for 30 minutes, and then neutralized with 0.1M boric acid for 10 minutes. After rinsing 3 times with PBS, 5% BSA was added dropwise for blocking at room temperature for 30 minutes; after discarding the liquid, a 1:200 diluted BrdU primary antibody (Boster Biotechnology, Wuhan) was added and incubated overnight at 4°C. The next day, discard the primary antibody, rinse with PBS 5 times; add 1:500 diluted fluorescent secondary antibody under light-proof conditions, incubate at room temperature for 1 hour, rinse with PBS 5 times; add 1:1000 diluted Hoechst dye under light-proof conditions, incubate at room temperature for 15-20 minutes, rinse with PBS twice, and add anti-fluorescence quencher. Under an inverted fluorescence microscope, randomly select 5-6 fields of view for observation and photography.
[0371] 5.3 Experimental Results
[0372] like Figure 1As shown in the figure, the proliferating HaCaT cells contain BrdU, so the positive cell nuclei show red fluorescence (as shown by the white triangle); while the Hoechst dye dyes all cell nuclei into blue. The number of positive cells in the Veh group HaCaT cells accounted for 1.7±1.2% of the total number of cells. After 100ng / mL IL-17 stimulation for 12 hours, the proportion of proliferating HaCaT cells increased to 5.8±1.0%; 100nM E37 alone treated HaCaT cells for 12 hours, the cell proliferation rate was 2.0±1.4%, which was not significantly different from that of the Veh group (P>0.05); 100nM E37 and 100ng / mL IL-17 co-treated HaCaT cells for 12 hours, the cell proliferation rate was 2.7±0.6%, which was significantly lower than that of the IL-17 treatment group (P<0.01).
[0373] 6. Evaluation of the efficacy of compounds in the treatment of psoriasis
[0374] 6.1 Pharmaceutical cream prescription process
[0375] The prescription of the medicated cream is shown in the following table:
[0376]
[0377] Preparation of aqueous phase: Weigh the prescribed amount of ethanol, add E37, stir to dissolve, add Tween 80, sodium dodecyl sulfate, glycerol, isopropyl myristate, methylparaben, azone, and purified water into the beaker in sequence, and stir until evenly dispersed.
[0378] Preparation of oil phase: Weigh the prescribed amount of glyceryl monostearate, palmitic acid, and white vaseline into a beaker, and heat in a water bath at 80°C to dissolve until liquid.
[0379] Slowly add the water phase into the oil phase while stirring. After all the water phase is added, take it out from the water bath and stir at room temperature until it cools into a cream.
[0380] 6.2 Imiquimod-induced psoriasis model in mice
[0381] 24 C57BL / 6 mice were purchased from the Experimental Animal Center of Nanjing Medical University, half male and half female, weighing 22-23g. The dorsal hair of the mice was shaved, and the mice were randomly divided into 4 groups according to gender: control group (Vas), model group (IMQ), model group + mometasone furoate group (IMQ+Mome) and model group + E37 cream group (IMQ+E37), 6 mice in each group. Before the experiment, the mice were placed in a quiet, light-avoiding environment for 3 days to adapt to the environment. The ratio of light to dark time was 1:1, the room temperature was controlled at 25°C, the humidity was 55%, and the mice were free to eat and drink water.
[0382] 62.5 mg 5% (0.1 g: 2 g) imiquimod ointment (Imiquimod, IMQ, 3M Company) was applied to the back skin of mice for 6 consecutive days to induce psoriasis-like skin lesions. The control group was given the same dose of vaseline ointment (Vaseline, Vas, Shandong Mingde Medical Technology Co., Ltd.). 6 hours after applying IMQ or Vas every day, 100 mg of positive drug 0.1% mometasone furoate cream (Mometasone, Mome, Shanghai Zhengda General Pharmaceutical Co., Ltd.) or E37 cream was applied. The Vas group was given the same dose of Vas. On the 1st, 3rd, and 5th days of modeling, the back skin of mice was photographed and recorded. The skin appearance on the 5th day of modeling was as follows: Figure 2 shown.
[0383] 6.3 Clinical symptom evaluation
[0384] The clinical symptoms of the mouse psoriasis model were evaluated using the Psoriasis Area and Severity Index (PASI) scoring standard, which uses three indicators: erythema, scaling, and infiltration and thickening. The scores were recorded from 0 to 4 points, and the scores of the three indicators were added together to obtain the total score. The PASI scoring standard is as follows: 0 points, no symptoms; 1 point, mild; 2 points, moderate; 3 points, severe; 4 points, extremely severe. Trained experimenters performed single-blind evaluations and took photos every day before applying IMQ cream. The scoring results are shown in the table below. Note: The quantitative data are expressed as mean ± standard deviation (mean ± SEM) and tested using two-way analysis of variance. In the analysis results, **P<0.01, relative to the Vas group; # P<0.05, ## P<0.01, relative to the IMQ group.
[0385] 6.4 Histopathological examination
[0386] The skin tissue of the dorsal administration area of the mice was collected and fixed in 4% (mass fraction) paraformaldehyde solution for 48 hours, then embedded in paraffin and sliced at 3 μm for hematoxylin-eosin (H&E) staining. The skin was observed and photographed at 100 times magnification using an Eclipse Ti inverted microscope, and the thickness of the epidermis was measured using NIS-element BR software. Three fields of view were randomly selected for each slice. Note: The quantitative data are expressed as mean ± standard deviation (mean ± SEM) and tested using one-way analysis of variance. In the analysis results, **P < 0.01, relative to the Vas group; ## P<0.01, relative to the IMQ group.
[0387] 6.5 Experimental Results
[0388] 6.5.1 Effect of E37 cream on the appearance of the back skin of psoriasis mice and PASI score
[0389] During the entire experiment, the back skin of mice in the Vas group remained smooth and flat, without symptoms such as erythema, scaling, and thickening ( Figure 2 The back skin of mice in the IMQ group showed obvious psoriasis-like symptoms such as erythema, scaling, and thickening on the third day of modeling, and the symptoms were significantly aggravated as the modeling progressed ( Figure 2 ), and on the 5th day, erythema, scaling (as shown by the black triangle), and thickening were the most serious; the PASI score showed that the PASI score of the IMQ group mice gradually increased, and from the 3rd day, there was a significant difference between the IMQ group and the Vas group (P<0.01) (Table 1). Applying the positive drug Mome can improve the appearance of psoriasis-like symptoms such as erythema, scaling, and thickening caused by IMQ in mice ( Figure 2 ); PASI scores showed that the PASI scores of mice in the IMQ+Mome group increased slowly. Starting from the 4th day, the PASI scores of the IMQ+Mome group were significantly lower than those of the IMQ group, which was statistically significant (P<0.01) (Table 1). Applying E37 cream can slightly improve the psoriasis-like symptoms of erythema, scaling, and thickening on the back skin of mice ( Figure 2 ), on the 5th day, the symptoms of erythema, scaling (as shown by the black triangle), and thickening in the IMQ+E37 group were alleviated compared with those in the IMQ group ( Figure 2 ), but the improvement effect was weaker than that of the positive drug Mome; PASI score showed that the PASI score of mice in the IMQ+E37 group increased slowly. From the 4th day, the PASI score of the IMQ+E37 group was lower than that of the IMQ group, which was statistically significant (P<0.05) (Table 1).
[0390] Table 1 PASI scores of the back skin of mice in each group
[0391]
[0392] 6.5.2 Effect of E37 cream on pathological changes of back skin of psoriasis mice
[0393] like Figure 3As shown in the figure, there was no obvious abnormality in the dorsal skin tissue structure of mice in the Vas group, the stratum corneum was completely keratinized, the boundary between the epidermis and dermis was clear, and the infiltration of inflammatory cells was less; the thickness of the epidermis was measured to be 25.72±1.19μm. The epidermis of the dorsal skin tissue of mice in the IMQ group was excessively thickened (as shown by the white straight line), the stratum corneum was not completely keratinized, and inflammatory cells were observed to aggregate in the stratum corneum (as shown by the black arrow), and the dermis was edematous with a large amount of inflammatory infiltration (as shown by the black triangle); the thickness of the epidermis was 108.48±3.51μm, which was significantly increased compared with the Vas group (P<0.01). The thickness of the epidermis of the dorsal skin tissue of mice in the IMQ+Mome group was 57.71±2.66μm, which was significantly lower than that in the IMQ group (P<0.01), no edema was observed in the dermis, and the degree of inflammatory cell infiltration was reduced compared with that in the IMQ group. The stratum corneum structure of the back skin tissue of mice in the IMQ+E37 group was slightly restored, and the thickness of the epidermis was 85.38±3.61μm, which was significantly lower than that in the IMQ group (P<0.01). The edema of the dermis was alleviated compared with that in the IMQ group, but there was still inflammatory cell infiltration (as shown by the black triangle).
[0394] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the preferred embodiments, ordinary technicians in the field should understand that the specific implementation methods of the present invention can still be modified or some technical features can be replaced by equivalents without departing from the spirit of the technical solution of the present invention, which should be included in the scope of the technical solution for protection of the present invention.
Claims
1. A fused pyrimidinedione compound and a pharmaceutically acceptable salt thereof, characterized in that: The structural formula of the compound is shown in formula (I), in, R 1 is a C1-C6 alkyl group; Each R 2 are independently halogen atoms; R 3 For unsubstituted C3-C 10 A cycloalkyl group or a C1-C6 alkyl group substituted with -OR4 or -N(R4)2; R 4 Each is independently selected from C1-C6 alkyl, C1-C6 alkyl substituted with C3-C8 cycloalkyl, C3-C8 cycloalkyl, phenyl; or Two R's 4 Together with N, they form a 4-8 membered heterocyclic ring, which is optionally substituted by 1-3 C1-C6 alkyl groups; n is an integer from 1 to 3; X is N; Y is ethynyl.
2. The compound according to claim 1 and its pharmaceutically acceptable salt, characterized in that: R 1 It is methyl, ethyl or isopropyl.
3. A fused pyrimidinedione compound and a pharmaceutically acceptable salt thereof, characterized in that: The compound is selected from:
4. Use of the compound according to any one of claims 1 to 3 or a pharmaceutically acceptable salt thereof in the preparation of TRPC4 and TRPC5 inhibitors.
5. Use of the compound according to any one of claims 1 to 3 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating diseases associated with abnormal function or expression of TRPC4 or / and TRPC5.
6. A pharmaceutical composition, characterized in that A compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 3, and a pharmaceutical excipient, comprising an effective therapeutic dose.
7. Use of the pharmaceutical composition according to claim 6 for preparing a drug for treating skin diseases associated with abnormal keratinocytes.
8. The use according to claim 7, characterized in that The disease is psoriasis, ichthyosis, palmoplantar keratoderma, Olmsted's disease, toad skin disease or menopausal keratoderma.
9. The use according to claim 7, characterized in that: The medicine is for topical use on the skin.
